<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotic prophylaxis for preventing burn wound infection - Barajas‐Nava, LA - 2013 | Cochrane Library</title> <meta content="Antibiotic prophylaxis for preventing burn wound infection - Barajas‐Nava, LA - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008738.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotic prophylaxis for preventing burn wound infection - Barajas‐Nava, LA - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008738.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008738.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotic prophylaxis for preventing burn wound infection" name="citation_title"/> <meta content="Leticia A Barajas‐Nava" name="citation_author"/> <meta content="Institute of Biomedical Research (IIB Sant Pau)" name="citation_author_institution"/> <meta content="leticia.barajas@cochrane.es" name="citation_author_email"/> <meta content="Jesús López‐Alcalde" name="citation_author"/> <meta content="Laín Entralgo Agency (Cochrane Collaborating Centre)" name="citation_author_institution"/> <meta content="Marta Roqué i Figuls" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP), Spain" name="citation_author_institution"/> <meta content="Ivan Solà" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP), Spain" name="citation_author_institution"/> <meta content="Xavier Bonfill Cosp" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP), Spain ‐ Universitat Autònoma de Barcelona" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD008738.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/06/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008738.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008738.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008738.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Bacterial Agents [adverse effects, *therapeutic use]; Antibiotic Prophylaxis [adverse effects, *methods]; Bandages; Burns [*complications]; Randomized Controlled Trials as Topic; Silver Sulfadiazine [adverse effects, therapeutic use]; Skin, Artificial; Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects, therapeutic use]; Wound Infection [chemically induced, *prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008738.pub2&amp;doi=10.1002/14651858.CD008738.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008738\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008738\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","pt","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008738.pub2",title:"Antibiotic prophylaxis for preventing burn wound infection",firstPublishedDate:"Jun 6, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008738.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008738.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008738.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008738.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008738.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008738.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008738.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008738.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008738.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008738.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>16487 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008738.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-sec-0196"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-sec-0036"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-sec-0041"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-sec-0042"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-sec-0183"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/appendices#CD008738-sec-0201"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/table_n/CD008738StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/table_n/CD008738StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotic prophylaxis for preventing burn wound infection</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information#CD008738-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Leticia A Barajas‐Nava</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information#CD008738-cr-0003">Jesús López‐Alcalde</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information#CD008738-cr-0004">Marta Roqué i Figuls</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information#CD008738-cr-0005">Ivan Solà</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information#CD008738-cr-0006">Xavier Bonfill Cosp</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information/en#CD008738-sec-0231">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 June 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008738.pub2">https://doi.org/10.1002/14651858.CD008738.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008738-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008738-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008738-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008738-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008738-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008738-abs-0003">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008738-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008738-abs-0001" lang="en"> <section id="CD008738-sec-0001"> <h3 class="title" id="CD008738-sec-0001">Background</h3> <p>Infection of burn wounds is a serious problem because it can delay healing, increase scarring and invasive infection may result in the death of the patient. Antibiotic prophylaxis is one of several interventions that may prevent burn wound infection and protect the burned patient from invasive infections. </p> </section> <section id="CD008738-sec-0002"> <h3 class="title" id="CD008738-sec-0002">Objectives</h3> <p>To assess the effects of antibiotic prophylaxis on rates of burn wound infection.</p> </section> <section id="CD008738-sec-0003"> <h3 class="title" id="CD008738-sec-0003">Search methods</h3> <p>In January 2013 we searched the Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid MEDLINE ‐ In‐Process &amp; Other Non‐Indexed Citations (2013); Ovid EMBASE; EBSCO CINAHL and reference lists of relevant articles. There were no restrictions with respect to language, date of publication or study setting. </p> </section> <section id="CD008738-sec-0004"> <h3 class="title" id="CD008738-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) that evaluated the efficacy and safety of antibiotic prophylaxis for the prevention of BWI. Quasi‐randomised studies were excluded. </p> </section> <section id="CD008738-sec-0005"> <h3 class="title" id="CD008738-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies, assessed the risk of bias, and extracted relevant data. Risk ratio (RR) and mean difference (MD) were estimated for dichotomous data and continuous data, respectively. When sufficient numbers of comparable RCTs were available, trials were pooled in a meta‐analysis to estimate the combined effect. </p> </section> <section id="CD008738-sec-0006"> <h3 class="title" id="CD008738-sec-0006">Main results</h3> <p>This review includes 36 RCTs (2117 participants); twenty six (72%) evaluated topical antibiotics, seven evaluated systemic antibiotics (four of these administered the antibiotic perioperatively and three administered upon hospital admission or during routine treatment), two evaluated prophylaxis with non absorbable antibiotics, and one evaluated local antibiotics administered via the airway. </p> <p>The 11 trials (645 participants) that evaluated topical prophylaxis with silver sulfadiazine were pooled in a meta analysis. There was a statistically significant increase in burn wound infection associated with silver sulfadiazine compared with dressings/skin substitute (OR = 1.87; 95% CI: 1.09 to 3.19, I<sup>2</sup> = 0%). These trials were at high, or unclear, risk of bias. Silver sulfadiazine was also associated with significantly longer length of hospital stay compared with dressings/skin substitute (MD = 2.11 days; 95% CI: 1.93 to 2.28). </p> <p>Systemic antibiotic prophylaxis in non‐surgical patients was evaluated in three trials (119 participants) and there was no evidence of an effect on rates of burn wound infection. Systemic antibiotics (trimethoprim‐sulfamethoxazole) were associated with a significant reduction in pneumonia (only one trial, 40 participants) (RR = 0.18; 95% CI: 0.05 to 0.72) but not sepsis (two trials 59 participants) (RR = 0.43; 95% CI: 0.12 to 1.61). </p> <p>Perioperative systemic antibiotic prophylaxis had no effect on any of the outcomes of this review. </p> <p>Selective decontamination of the digestive tract with non‐absorbable antibiotics had no significant effect on rates of all types of infection (2 trials, 140 participants). Moreover, there was a statistically significant increase in rates of MRSA associated with use of non‐absorbable antibiotics plus cefotaxime compared with placebo (RR = 2.22; 95% CI: 1.21 to 4.07). </p> <p>There was no evidence of a difference in mortality or rates of sepsis with local airway antibiotic prophylaxis compared with placebo (only one trial, 30 participants). </p> </section> <section id="CD008738-sec-0007"> <h3 class="title" id="CD008738-sec-0007">Authors' conclusions</h3> <p>The conclusions we are able to draw regarding the effects of prophylactic antibiotics in people with burns are limited by the volume and quality of the existing research (largely small numbers of small studies at unclear or high risk of bias for each comparison). The largest volume of evidence suggests that topical silver sulfadiazine is associated with a significant increase in rates of burn wound infection and increased length of hospital stay compared with dressings or skin substitutes; this evidence is at unclear or high risk of bias. Currently the effects of other forms of antibiotic prophylaxis on burn wound infection are unclear. One small study reported a reduction in incidence of pneumonia associated with a specific systematic antibiotic regimen. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008738-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008738-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008738-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008738-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008738-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008738-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008738-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008738-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008738-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008738-abs-0006" lang="en"> <h3>Antibiotics to prevent burn wounds becoming infected</h3> <p>Burn injuries are a serious problem. They are associated with a significant incidence of death and disability, multiple surgical procedures, prolonged hospitalisation, and high costs of health care. </p> <p>Various antibiotics are used with the aim of reducing the risk of infection in burn patients before it occurs. Some antibiotics are used locally on the skin (topical treatments), others are taken orally, or by injection, and affect the whole body (systemic treatments). It is not clear if prophylactic antibiotics are beneficial. </p> <p>Thirty six studies involving 2117 participants are included in this review. The studies compared people with burns who were given antibiotics with people also with burns who received either an inactive treatment (placebo), no treatment, wound dressings, or another topical preparation or antibiotic. Twenty‐six trials (72%) evaluated topical antibiotics and smaller numbers evaluated antibiotics given orally, intravenously or via the airway. Most studies were small and of poor quality. </p> <p>There was some evidence that a particular antibiotic (silver sulfadiazine) applied directly to the burn actually increases the rates of infection by between 8% and 80%. Otherwise there was not enough research evidence about the effects of antibiotics to enable reliable conclusions to be drawn. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008738-sec-0196" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008738-sec-0196"></div> <h3 class="title" id="CD008738-sec-0197">Implications for practice</h3> <section id="CD008738-sec-0197"> <p>The available evidence is limited and, in general, does not demonstrate that antibiotic prophylaxis reduces the risk of burn wound infection, invasive infections, or mortality associated with infection. </p> <p>The use of topical antibiotics in burn wounds needs to be reconsidered,and specifically the use of SSD, since the available evidence suggests that patients treated with topical silver sulfadiazine have a higher risk of burn wound infection and longer length of hospital stay than those treated with dressings. The evidence concerning the safety of antibiotic prophylaxis is limited, and it is not possible to generate conclusions about it, although one study suggested that patients treated with selective digestive tract decontamination had a higher frequency of adverse events than those treated with placebo. </p> </section> <h3 class="title" id="CD008738-sec-0198">Implications for research</h3> <section id="CD008738-sec-0198"> <p>The results of this review suggest that the effects of antibiotic prophylaxis in burn patients have not been studied sufficiently. Clinical trials with adequate statistical power are required to evaluate the effects of the different modalities of antibiotic prophylaxis (topical, general systemic, perioperative systemic, selective digestive decontamination, and delivered by airway), compared with placebo or standard treatment on the prevention of burn wound infection (burn wound infection), other infections, or mortality associated with infection. The safety of these interventions is to be determined. Additionally, an economic evaluation of such interventions is warranted. </p> <p>Future randomised trials should be designed and conducted rigorously. The design and implementation of future studies must guarantee adequate generation and concealment of the randomisation sequence, as well as blinding of participants and evaluators of outcomes. In addition, researchers must ensure proper monitoring of participants, minimize losses, and handle losses in agreement with sound statistical analysis. With specific reference to trials that randomise burns on the same person to different interventions, methodological characteristics inherent to this type of design must be taken into account (<a href="./references#CD008738-bbs2-0102" title="LouisTA , LavoriPW , BailarJC , PolanskyM . Crossover and self‐controlled designs in clinical research. New England Journal of Medicine1984;310:24‐31. ">Louis 1984</a>; <a href="./references#CD008738-bbs2-0107" title="MillsEJ ,  ChanAW ,  WuP ,  VailA ,  GuyattGH ,  AltmanDG . Design, analysis, and presentation of crossover trials. Trials2009;10:27. ">Mills 2009</a>). Many of these characteristics are present in self‐controlled trials, and should be considered when pre‐determining the sample size and analysing the data, ideally with the advice of a statistician. The corresponding reports should present relevant information in a clear manner, and allow critical appraisal of their methodology, results and applicability. It is recommended that they abide by the guidelines of the CONSORT declaration for clinical trials (<a href="./references#CD008738-bbs2-0110" title="MoherD ,  SchulzKF ,  AltmanD ,  CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285(15):1987‐91. ">Moher 2001</a>; <a href="./references#CD008738-bbs2-0123" title="SchulzKF ,  AltmanDG ,  MoherD ,  CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine2010;152(11):726‐32. ">Schulz 2010</a>), or any of its extensions, when pertinent (<a href="./references#CD008738-bbs2-0080" title="BoutronI ,  MoherD ,  AltmanDG ,  SchulzKF ,  RavaudP ,  CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Annals of Internal Medicine2008;148(4):295‐309. ">Boutron 2008</a>). </p> <p>As for the participants, it is necessary to define the degree of burns clearly; describing depth and total body surface burned to allow assessment of the applicability of the interventions tested. There should be a protocol for management and burn care that must be applied consistently across study arms, so that the effect of antibiotic prophylaxis can be determined. In addition, consensus is needed amongst researchers and clinicians regarding valid and reproducible criteria for diagnosis of infection of the burn and a consistent and standardised approach to outcome reporting. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008738-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008738-sec-0036"></div> <section id="CD008738-sec-0037"> <h3 class="title" id="CD008738-sec-0037">Description of the condition</h3> <p>The <i>International Society for Burn Injuries</i> defines a burn as an injury to the skin or other organic tissue caused by thermal trauma (<a href="./references#CD008738-bbs2-0098" title="LatarjetJ . A simple guide to burn treatment. International Society for Burn Injuries in collaboration with the World Health Organization. Burns1995;21(3):221‐5. ">Latarjet 1995</a>). A skin burn is the destruction of some, or all, of the different layers of cells in the skin by a hot liquid (scald), a hot solid (contact burn), or a flame (flame burn). Skin injuries due to ultraviolet radiation, radioactivity, electricity or chemicals, as well as respiratory damage resulting from smoke inhalation, are also considered to be burns (<a href="./references#CD008738-bbs2-0098" title="LatarjetJ . A simple guide to burn treatment. International Society for Burn Injuries in collaboration with the World Health Organization. Burns1995;21(3):221‐5. ">Latarjet 1995</a>; <a href="./references#CD008738-bbs2-0117" title="PedenM , McGeeK , SharmaG . The injury chart book: a graphical overview of the global burden of injuries. World Health Organization, 2002. ">Peden 2002</a>; <a href="./references#CD008738-bbs2-0118" title="PedenM , OyegbiteK , Ozanne‐SmithJ , HyderAA , BrancheC , Fazlur RahmanAKM , et al. World report on child injury prevention. World Health Organization. Geneva, 2008. ">Peden 2008</a>; <a href="./references#CD008738-bbs2-0135" title="Facts about injuries: burns. World Health Organization and International Society for Burns Injuries. Geneva, 2006. ">WHO 2006</a>). </p> <p>Burn injuries are a major source of morbidity and mortality; they represent a public health problem and a significant burden to the health care system (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0135" title="Facts about injuries: burns. World Health Organization and International Society for Burns Injuries. Geneva, 2006. ">WHO 2006</a>). Every year, more than 300,000 people worldwide die from fire‐related burns, most of them (i.e. 90%) occurring in low and middle‐income countries (<a href="./references#CD008738-bbs2-0109" title="MockC , PeckM , PedenM , KrugE , AhujaR , AlbertynH , et al. A WHO plan for burn prevention and care. World Health Organization. Geneva, 2008. ">Mock 2008</a>; <a href="./references#CD008738-bbs2-0117" title="PedenM , McGeeK , SharmaG . The injury chart book: a graphical overview of the global burden of injuries. World Health Organization, 2002. ">Peden 2002</a>). However, burns also represent one of the main causes of injury‐related death in some high‐income countries, such as  the USA and certain European countries (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0096" title="HyderAA , PedenM , KrugE . Child health must include injury prevention. Lancet2009;373(9658):102‐3. ">Hyder 2009</a>; <a href="./references#CD008738-bbs2-0103" title="MathersCD , BernardC , IburgKM , InoueM , Ma FatD , ShibuyaK , et al. Global burden of disease in 2002: data sources, methods and results. World Health Organization. Geneva, 2003. ">Mathers 2003</a>; <a href="./references#CD008738-bbs2-0108" title="MiniñoAM , AndersonRN , FingerhutLA , BoudreaultMA , WarnerM . Deaths: injuries, 2002. National Vital Statistics Reports2006;54(10):1‐124. ">Miniño 2006</a>; <a href="./references#CD008738-bbs2-0135" title="Facts about injuries: burns. World Health Organization and International Society for Burns Injuries. Geneva, 2006. ">WHO 2006</a>). Millions of burn victims suffer permanent disability and disfigurement, which is often stigmatising; it is estimated that 10 million disability‐adjusted life years are lost each year at a worldwide level through burn injury (<a href="./references#CD008738-bbs2-0096" title="HyderAA , PedenM , KrugE . Child health must include injury prevention. Lancet2009;373(9658):102‐3. ">Hyder 2009</a>; <a href="./references#CD008738-bbs2-0109" title="MockC , PeckM , PedenM , KrugE , AhujaR , AlbertynH , et al. A WHO plan for burn prevention and care. World Health Organization. Geneva, 2008. ">Mock 2008</a>; <a href="./references#CD008738-bbs2-0118" title="PedenM , OyegbiteK , Ozanne‐SmithJ , HyderAA , BrancheC , Fazlur RahmanAKM , et al. World report on child injury prevention. World Health Organization. Geneva, 2008. ">Peden 2008</a>). Burns create a heavy economic burden for health services. Treatment costs depend upon the type and severity of the burn, as well as associated costs such as hospitalisation, the need for long‐term rehabilitation, the loss of schooling/absence from work, future unemployment, and social rejection. In spite of this, there are actually very few studies that provide evidence of the overall impact and cost of burns (<a href="./references#CD008738-bbs2-0109" title="MockC , PeckM , PedenM , KrugE , AhujaR , AlbertynH , et al. A WHO plan for burn prevention and care. World Health Organization. Geneva, 2008. ">Mock 2008</a>; <a href="./references#CD008738-bbs2-0118" title="PedenM , OyegbiteK , Ozanne‐SmithJ , HyderAA , BrancheC , Fazlur RahmanAKM , et al. World report on child injury prevention. World Health Organization. Geneva, 2008. ">Peden 2008</a>). </p> <p>Infections are considered to be one of the most important and potentially serious complications in people with burns (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0113" title="MurrayC , HospenthalDR . Burn Wound Infections. eMedicine Infectious Diseases (http://emedicine.medscape.com/article/213595‐overview)2008. ">Murray 2008</a>). A report by the National Burn Repository of the United States mentions that in a 10‐year period there were 19,655 cases of complications in people with burns; 31% of these were pulmonary complications, 17% were related to the wound infection and cellulitis, and 15% were due to septicaemia and other infectious complications (<a href="./references#CD008738-bbs2-0099" title="LatenserBA , MillerSF , BesseyPQ , BrowningSM , CarusoDM , GomezM , et al. National Burn Repository 2006: a ten‐year review. Journal of Burn Care and Research2007;28(5):635‐58. ">Latenser 2007</a>; <a href="./references#CD008738-bbs2-0113" title="MurrayC , HospenthalDR . Burn Wound Infections. eMedicine Infectious Diseases (http://emedicine.medscape.com/article/213595‐overview)2008. ">Murray 2008</a>). These data are supported by similar reports carried out in other countries (<a href="./references#CD008738-bbs2-0073" title="AlpE ,  CoruhA ,  GunayGK ,  YontarY ,  DoganayM . Risk factors for nosocomial infection and mortality in burn patients: 10 years of experience at a university hospital. Journal of Burn Care and Research2012;33(3):379‐85. ">Alp 2012</a><i>;</i><a href="./references#CD008738-bbs2-0124" title="Sociedad Española de MedicinaPreventiva , Salud Públicae Higiene (SEMPSPH) . Estudio de prevalencia de las infecciones nosocomiales en España EPINE 1990‐2007: 18 años. Madrid, 2012:59 p. ">SEMPSPH 2008</a>; <a href="./references#CD008738-bbs2-0129" title="Soares de MacedoJL ,  SantosJB . Nosocomial infections in a Brazilian burn unit. Burns2006;32(4):477‐81. ">Soares 2006</a>). </p> <p>Infections generally arise in the acute period after the burn injury (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0126" title="SheridanRL . Sepsis in pediatric burn patients. Pediatric Critical Care Medicine2005;6(3 Suppl):S112‐9. ">Sheridan 2005</a>). Burn wounds are highly susceptible to infection due to the loss of skin integrity and the reduction of immunity mediated by the cells. Once the physical barrier of the skin has been compromised, there is potential for the invasion of microbes into the body (<a href="./references#CD008738-bbs2-0113" title="MurrayC , HospenthalDR . Burn Wound Infections. eMedicine Infectious Diseases (http://emedicine.medscape.com/article/213595‐overview)2008. ">Murray 2008</a>; <a href="./references#CD008738-bbs2-0125" title="SharmaBR . Infection in patients with severe burns: causes and prevention thereof. Infectious Disease Clinics of North America2007;21(3):745‐59, ix. ">Sharma 2007</a>). An area of dead tissue, with few or no blood vessels (avascular necrotic tissue (eschar)) replaces the skin and, eventually, will be colonised with micro‐organisms (<a href="./references#CD008738-bbs2-0084" title="DeMacedoJL , SantosJB . Bacterial and fungal colonization of burn wounds. Memórias do Instituto Oswaldo Cruz2005;100(5):535‐9. ">De Macedo 2005</a>; <a href="./references#CD008738-bbs2-0089" title="ErolS , AltoparlakU , AkcayMN , CelebiF , ParlakM . Changes of microbial flora and wound colonization in burned patients. Burns2004;30(4):357‐61. ">Erol 2004</a>; <a href="./references#CD008738-bbs2-0125" title="SharmaBR . Infection in patients with severe burns: causes and prevention thereof. Infectious Disease Clinics of North America2007;21(3):745‐59, ix. ">Sharma 2007</a>). The proliferation of micro‐organisms in the burn wound may be followed by tissue invasion, giving rise to burn wound infection (BWI) and invasive (systemic) infections. Common invasive infections in people with burns include pulmonary infections, urinary tract infection, bacteraemia and sepsis (<a href="./references#CD008738-bbs2-0076" title="AnserminoM , HemsleyC . Intensive care management and control of infection. BMJ2004;329(7459):220‐3. ">Ansermino 2004</a>; <a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0120" title="PruittBAJr , McManusAT , KimSH , GoodwinCW . Burn wound infections: current status. World Journal of Surgery1998;22(2):135‐45. ">Pruitt 1998</a>). Burn injury also has a severe impact on the host’s immune system, resulting in a general impairment of the host defences (<a href="./references#CD008738-bbs2-0111" title="MunsterAM . Immunologic response of trauma and burns. An overview. American Journal of Medicine1984;76(3A):142‐5. ">Munster 1984</a>; <a href="./references#CD008738-bbs2-0125" title="SharmaBR . Infection in patients with severe burns: causes and prevention thereof. Infectious Disease Clinics of North America2007;21(3):745‐59, ix. ">Sharma 2007</a>). </p> <p>Deciding whether a burn wound is infected can be difficult. Firstly, the inflammation resulting from the injury can mimic that seen with infection. Secondly, the interpretation of surface cultures is often difficult due to the extensive and rapid microbial colonisation of the wound (<a href="./references#CD008738-bbs2-0076" title="AnserminoM , HemsleyC . Intensive care management and control of infection. BMJ2004;329(7459):220‐3. ">Ansermino 2004</a>), with micro‐organisms coming from the persons skin or from external sources (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0089" title="ErolS , AltoparlakU , AkcayMN , CelebiF , ParlakM . Changes of microbial flora and wound colonization in burned patients. Burns2004;30(4):357‐61. ">Erol 2004</a>; <a href="./references#CD008738-bbs2-0137" title="WurtzR , KarajovicM , DacumosE , JovanovicB , HanumadassM . Nososcomial Infections in a burns intensive care unit. Burns1995;21(3):181‐4. ">Wurtz 1995</a>). </p> <p>The nature and extent of the burn wound, together with the type and amount of colonising micro‐organisms can influence the risk of invasive infection. The spectrum of infective agents that can be present in the burn wounds varies. Nowadays, Gram‐positive bacteria such as <i>Staphylococcus aureus</i> , and Gram‐negative bacteria such as <i>Pseudomona aeruginosa</i> are the predominant pathogens. Nonetheless, other micro‐organisms, such as fungi, rickettsias and viruses, can also be implicated (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0104" title="MayahallCG . The epidemiology of burn wound infections: then and now. Clinical Infectious Diseases2003;37(4):543‐50. ">Mayhall 2003</a>; <a href="./references#CD008738-bbs2-0119" title="PolavarapuN , OgilvieMP , PanthakiZJ . Microbiology of burn wound infections. Journal of Craniofacial Surgery2008;19(4):899‐902. ">Polavarapu 2008</a>; <a href="./references#CD008738-bbs2-0125" title="SharmaBR . Infection in patients with severe burns: causes and prevention thereof. Infectious Disease Clinics of North America2007;21(3):745‐59, ix. ">Sharma 2007</a>). It should also be noted that multidrug‐resistant micro‐organisms, such as methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA), are pathogens frequently identified in burns (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0086" title="DeSantiL . Pathophysiology and current management of burn injury. Advances in Skin and Wound Care2005;18(6):323‐32; quiz 332‐4. ">DeSanti 2005</a>; <a href="./references#CD008738-bbs2-0104" title="MayahallCG . The epidemiology of burn wound infections: then and now. Clinical Infectious Diseases2003;37(4):543‐50. ">Mayhall 2003</a>; <a href="./references#CD008738-bbs2-0125" title="SharmaBR . Infection in patients with severe burns: causes and prevention thereof. Infectious Disease Clinics of North America2007;21(3):745‐59, ix. ">Sharma 2007</a>).  </p> <p>Burn wound infection (BWI) is a serious problem: it can delay wound healing, can increase the scarring and can favour the proliferation of micro‐organisms that may result in invasive infections (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0087" title="EdwardsR , HardingKG . Bacteria and wound healing. Current Opinion in Infectious Diseases2004;17(2):91‐6. ">Edwards 2004</a>; <a href="./references#CD008738-bbs2-0128" title="SingerAJ , McClainSA . Persistent wound infection delays epidermal maturation and increases scarring in thermal burns. Wound Repair and Regeneration2002;10(6):372‐7. ">Singer 2002</a>). Nowadays, after the initial resuscitation of burn victims, up to 75% of all deaths are a consequence of infection, rather than sudden cellular fluid imbalance (osmotic shock) and decreased volume of blood plasma (hypovolaemia) (<a href="./references#CD008738-bbs2-0076" title="AnserminoM , HemsleyC . Intensive care management and control of infection. BMJ2004;329(7459):220‐3. ">Ansermino 2004</a>; <a href="./references#CD008738-bbs2-0079" title="BangRL , SharmaPN , SanyalSC , Al NaijadahI . Septicaemia after burn injury: a comparative study. Burns2002;28(8):746‐51. ">Bang 2002</a>; <a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0125" title="SharmaBR . Infection in patients with severe burns: causes and prevention thereof. Infectious Disease Clinics of North America2007;21(3):745‐59, ix. ">Sharma 2007</a>; <a href="./references#CD008738-bbs2-0126" title="SheridanRL . Sepsis in pediatric burn patients. Pediatric Critical Care Medicine2005;6(3 Suppl):S112‐9. ">Sheridan 2005</a>). </p> </section> <section id="CD008738-sec-0038"> <h3 class="title" id="CD008738-sec-0038">Description of the intervention</h3> <p>Prevention of infection of burn wounds requires a team approach, and should be an early focus of the care of burned patients, with particular consideration given to infection‐control practices and long‐term rehabilitative care (<a href="./references#CD008738-bbs2-0113" title="MurrayC , HospenthalDR . Burn Wound Infections. eMedicine Infectious Diseases (http://emedicine.medscape.com/article/213595‐overview)2008. ">Murray 2008</a>). </p> <p>A variety of interventions exists for preventing infections in burn wounds: namely, early removal of full‐thickness burned tissue (debridement); early definitive wound closure; strict enforcement of infection‐control procedures (hand washing, use of personal protective equipment, i.e. gown, gloves, and masks); and the use of antimicrobial prophylaxis (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0086" title="DeSantiL . Pathophysiology and current management of burn injury. Advances in Skin and Wound Care2005;18(6):323‐32; quiz 332‐4. ">DeSanti 2005</a>; <a href="./references#CD008738-bbs2-0113" title="MurrayC , HospenthalDR . Burn Wound Infections. eMedicine Infectious Diseases (http://emedicine.medscape.com/article/213595‐overview)2008. ">Murray 2008</a>; <a href="./references#CD008738-bbs2-0133" title="WeberJM , SheridanRL , SchulzJT , TompkinsRG , RyanCM . Effectiveness of bacteria controlled nursing units in preventing cross‐colonization with resistant bacteria in severely burned children. Infection Control and Hospital Epidemiology2002;23(9):549‐51. ">Weber 2002</a>; <a href="./references#CD008738-bbs2-0134" title="WeberJ , McManusA . Infection control in burn patients. Burns2004;30(8):A16‐24. ">Weber 2004</a>). There is a wide variety of topical antimicrobial agents available for use as prophylaxis for BWI, such as silver nitrate and silver sulphadiazine (<a href="./references#CD008738-bbs2-0076" title="AnserminoM , HemsleyC . Intensive care management and control of infection. BMJ2004;329(7459):220‐3. ">Ansermino 2004</a>; <a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>). Moreover, topical antimicrobials have been used together with systemic (whole body) antibiotics to prevent and treat infection. A range of antibiotics, and routes of administration have been evaluated for the prevention of systemic infection in people with burn wounds. For example, oral trimethoprim‐sulphamethoxazole prophylaxis and intravenous cephalothin prophylaxis (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>). </p> <p>To address complications of smoke inhalation, local antibiotic prophylaxis administered via the airway has been tested by using aerosolized antibiotics (<a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>). The most recent clinical practice guidelines, however, do not recommend the routine administration of prophylactic antibiotics in burned persons. Antibiotics are recommended only for patients with known infections (<a href="./references#CD008738-bbs2-0074" title="AlsbjörnB , GilbertP , HartmannB , KaźmierskiM , MonstreyS , PalaoR , et al. Guidelines for the management of partial‐thickness burns in a general hospital or community setting recommendations of a European working party. Burns2007;33(2):155‐60. ">Alsbjörn 2007</a>; <a href="./references#CD008738-bbs2-0081" title="BrychtaP , MagnetteA .  . European Practice Guidelines for Burn Care. The Netherlands, 2011. ">Brychta 2011</a><i>;</i><a href="./references#CD008738-bbs2-0095" title="HospenthalDR ,  MurrayCK ,  AndersenRC ,  BellRB ,  CalhounJH ,  CancioLC , et al. Guidelines for the prevention of infections associated with combat‐related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. Journal of Trauma2011;71(Suppl 2):S210‐34. ">Hospenthal 2011</a>; <a href="./references#CD008738-bbs2-0114" title="NSW Severe Burn Injury Service (SBIS). Clinical Practice Guidelines Burn Wound Management. New South Wales, 2008. ">NSW Severe Burn Injury Service 2008</a>). Before the wide adoption of early excision and closure of deep wounds, infection was a frequent occurrence in the burn wound (<a href="./references#CD008738-bbs2-0126" title="SheridanRL . Sepsis in pediatric burn patients. Pediatric Critical Care Medicine2005;6(3 Suppl):S112‐9. ">Sheridan 2005</a>). Nowadays, however, the early excision of eschar and avascularised tissues improves the perfusion of the burned tissues, and allows systemic antibiotics to reach adequate therapeutic levels in the burn wound (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0097" title="KumarP . Prophylactic antibiotics in burns. Burns2006;32(5):655‐6. ">Kumar 2006</a>; <a href="./references#CD008738-bbs2-0104" title="MayahallCG . The epidemiology of burn wound infections: then and now. Clinical Infectious Diseases2003;37(4):543‐50. ">Mayhall 2003</a>). Despite the fact that systemic infection, such as sepsis, is now less frequent, infection in people with burns continues to be a serious threat (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0097" title="KumarP . Prophylactic antibiotics in burns. Burns2006;32(5):655‐6. ">Kumar 2006</a>; <a href="./references#CD008738-bbs2-0126" title="SheridanRL . Sepsis in pediatric burn patients. Pediatric Critical Care Medicine2005;6(3 Suppl):S112‐9. ">Sheridan 2005</a>). </p> <p>This review will focus on the effects of antibiotic prophylaxis (oral (PO), parenteral (entry to body not via gastrointestinal tract) or topical antimicrobials) for preventing burn wound infections. </p> </section> <section id="CD008738-sec-0039"> <h3 class="title" id="CD008738-sec-0039">How the intervention might work</h3> <p>Improvements in recovery for seriously burned people have been attributed to medical advances in wound care and infection control practices (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0086" title="DeSantiL . Pathophysiology and current management of burn injury. Advances in Skin and Wound Care2005;18(6):323‐32; quiz 332‐4. ">DeSanti 2005</a>). </p> <p>The efficacy of commonly‐used antimicrobial agents in burns units is dynamic due to the ability of micro‐organisms to develop resistance quickly (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0104" title="MayahallCG . The epidemiology of burn wound infections: then and now. Clinical Infectious Diseases2003;37(4):543‐50. ">Mayhall 2003</a>). The antibiotic regimen of choice is determined by the pathogen known, or suspected, to cause the infection (<a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>). The use of an effective antimicrobial agent, however, could reduce substantially the microbial load in the open surface of the burn wound, and, therefore, reduce the risk of infection. Bearing the above in mind, antibiotic prophylaxis might be a useful way of protecting burn victims against wound, and invasive, infections. </p> </section> <section id="CD008738-sec-0040"> <h3 class="title" id="CD008738-sec-0040">Why it is important to do this review</h3> <p>The use of antibiotics has been considered useful in treatment of infections in burn victims (<a href="./references#CD008738-bbs2-0119" title="PolavarapuN , OgilvieMP , PanthakiZJ . Microbiology of burn wound infections. Journal of Craniofacial Surgery2008;19(4):899‐902. ">Polavarapu 2008</a>). In some centres, patients with evidence of a positive microbiological culture from a burn site were given systemic antibiotic prophylaxis in an attempt to prevent wound infection and sepsis (<a href="./references#CD008738-bbs2-0077" title="AtoyebiOA , SowemimoGO , OdugbemiT . Bacterial flora of burn wounds in Lagos, Nigeria: a prospective study. Burns1992;18(6):448‐51. ">Atoyebi 1992</a>; <a href="./references#CD008738-bbs2-0090" title="HaqA . Pattern of burn injuries at a Kenyan provincial hospital. Burns1990;16(3):185‐9. ">Haq 1990</a>; <a href="./references#CD008738-bbs2-0100" title="LeeF , WongP , HillF , BurgnerD , TaylorR . Evidence behind the WHO guidelines: Hospital care for children: What is the role of prophylactic antibiotics in the management of burns?. Journal of Tropical Pediatrics2009;55(2):73‐7. ">Lee 2009</a>; <a href="./references#CD008738-bbs2-0116" title="OnubaO , UdoidiokE . Hospital management of massive burns in the developing countries. Burns, Including Thermal Injury1987;13(5):386‐90. ">Onuba 1987</a>), though this is now controversial (<a href="./references#CD008738-bbs2-0076" title="AnserminoM , HemsleyC . Intensive care management and control of infection. BMJ2004;329(7459):220‐3. ">Ansermino 2004</a>). There is thought to be a paucity of high quality research evidence to determine the effectiveness and cost‐efficiency of antibiotic prophylaxis for preventing BWI (<a href="./references#CD008738-bbs2-0078" title="AvniT , LevcovichA , Ad‐ElDD , LeiboviciL , PaulM . Prophylactic antibiotics for burns patients: systematic review and meta‐analysis. BMJ2010;340:c241. ">Avni 2010</a>; <a href="./references#CD008738-bbs2-0100" title="LeeF , WongP , HillF , BurgnerD , TaylorR . Evidence behind the WHO guidelines: Hospital care for children: What is the role of prophylactic antibiotics in the management of burns?. Journal of Tropical Pediatrics2009;55(2):73‐7. ">Lee 2009</a>; <a href="./references#CD008738-bbs2-0067" title="UgburoAO , AtoyebiOA , OyeneyinJO , SowemimoGO . An evaluation of the role of systemic antibiotic prophylaxis in the control of burn wound infection at the Lagos University Teaching Hospital. Burns2004;30(1):43‐8. ">Ugburo 2004</a>). Moreover, the use of prophylactic antibiotics may not be safe: it may increase the risk of diarrhoea due to overgrowth of toxigenic strains of <i>Clostridium difficile</i> and other secondary infections, allergic reactions to the drug or bone marrow suppression (<a href="./references#CD008738-bbs2-0072" title="AlexanderJW . When should prophylactic antibiotics be given?. Annals of Surgery2009;249(4):557‐8. ">Alexander 2009</a>; <a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0088" title="ErgünO , CelikA , ErgunG , OzokG . Prophylactic antibiotic use in pediatric burn units. European Journal of Pediatric Surgery2004;14(6):422‐6. ">Ergün 2004</a>; <a href="./references#CD008738-bbs2-0131" title="StillJ , LawE , FriedmanB , NewtonT , WilsonJ . Clostridium difficile diarrhea on a burn unit. Burns2002;28(4):398‐9. ">Still 2002</a>). Finally, it may also promote the emergence of resistant strains of micro‐organisms, making the treatment of infections even more difficult (<a href="./references#CD008738-bbs2-0075" title="AltoparlakU , ErolS , AkcayMN , CelebiF , KadanaliA . The time‐related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns2004;30(7):660‐4. ">Altoparlak 2004</a>; <a href="./references#CD008738-bbs2-0082" title="ChurchD , ElsayedS , ReidO , WinstonB , LindsayR . Burn wound infections. Clinical Microbiology Reviews2006;19(2):403‐34. ">Church 2006</a>; <a href="./references#CD008738-bbs2-0112" title="MurphyKD , LeeJO , HerndonDN . Current pharmacotherapy for the treatment of severe burns. Expert Opinion on Pharmacotherapy2003;4(3):369‐84. ">Murphy 2003</a>). </p> <p>There is considerable debate concerning the use of antibiotic prophylaxis for the prevention of the BWI and therefore a Cochrane systematic review of the available evidence is warranted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008738-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008738-sec-0041"></div> <p>To assess the effects of antibiotic prophylaxis on rates of burn wound infection.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008738-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008738-sec-0042"></div> <section id="CD008738-sec-0043"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008738-sec-0044"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), published or unpublished, with allocation to interventions at the individual level (patient‐RCT) or at the group level (cluster‐RCT), testing the efficacy and safety of antibiotic prophylaxis for the prevention of burn wound infections. Quasi‐randomised studies were excluded. </p> </section> <section id="CD008738-sec-0045"> <h4 class="title">Types of participants</h4> <p>People of any age or gender, with any type of burn injury to the epidermis, dermis, subcutaneous tissues, vessels, nerve, tendons, or bone; but not residual burn wounds (these type of wounds may have had previous infections or treatments) admitted to any unit in the hospital setting, or treated in an outpatient setting. </p> <p>We included studies regardless of the severity of the burn (determined by either clinical evaluation or objective assessment, or both) or the type of burn injury (e.g. chemical, scald, or flame). We did not exclude studies depending on the presence of inhalation injury or co‐morbidity. </p> <p>We excluded studies that contained mixed population, i.e. people with already infected wounds in addition to those without an infection (unless the data were presented separately). </p> </section> <section id="CD008738-sec-0046"> <h4 class="title">Types of interventions</h4> <p>Prophylaxis was defined as the administration of antibiotics to patients without a documented infection, regardless of the signs of systemic inflammation, with the aim of preventing burn wound infection and invasive infection. Studies of the treatment of residual burn wounds was not included since the objective of this review is to assess the effect of first intention prophylaxis. </p> <p>We included any of the following antibiotic prophylaxis:</p> <p> <ul id="CD008738-list-0001"> <li> <p>Systemic antibiotics given orally or parenterally (intravenously or via intramuscular injection). </p> </li> <li> <p>Selective intestinal decontamination with antibiotics (non‐absorbable antibiotic therapy).</p> </li> <li> <p>Topical antibiotics, such as topical antimicrobial dressings or ointments (<a href="./references#CD008738-bbs2-0105" title="Merriam‐Webster's Collegiate® Dictionary, Eleventh Edition. Available from www.merriam‐webster.com/ (accessed 2 May 2012). ">Merriam‐Webster 2012</a>). </p> </li> <li> <p>Local airway prophylaxis, such as aerosolised antibiotics.</p> </li> </ul> </p> <p>Eligible comparisons were placebo, no treatment, usual care or an alternative intervention. Alternative interventions could include non pharmacological measures such as isolation of the burn patient, surgical excision; or pharmacological measures, such as another antibiotic regimen. Trials comparing different antibiotics or different antibiotic dosages, routes of administration, timings or duration of administration were eligible for inclusion. Antibiotic prophylaxis could be given at any moment after admission ('general prophylaxis') or could be specifically given before surgical procedures ('perioperative prophylaxis'). We did not have a minimum duration of the intervention or of follow‐up as inclusion criteria. </p> <p>We excluded studies evaluating antibiotic‐impregnated catheters; ointments or dressings that contained antimicrobials (iodine, chlorhexidine); and antifungals, since they are not considered to be antibiotic therapies. Dressings for superficial partial‐thickness burns are evaluated in another Cochrane review (<a href="./references#CD008738-bbs2-0132" title="WasiakJ , ClelandH , CampbellF . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD002106.pub3] ">Wasiak 2008</a>), the principal objective of which was not the evaluation of antibiotic prophylaxis. </p> </section> <section id="CD008738-sec-0047"> <h4 class="title">Types of outcome measures</h4> <section id="CD008738-sec-0048"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008738-list-0002"> <li> <p><b>Outcome 1:</b>Burn wound infection: studies reporting an objective measure of burn wound infection. Diagnosis should rely on clinical examination (burn wound appearance) and culture data, if possible, however, burn wound infections diagnosed only by clinical examination were also eligible. </p> </li> <li> <p><b>Outcome 2:</b> Invasive infections, such as pneumonia, urinary tract infections (UTI), bacteraemia or blood infections (sepsis), or central venous catheter‐associated bloodstream infections. We admitted any measure for quantifying infections, such as incidence rate or incidence density rate. </p> </li> <li> <p><b>Outcome 3:</b> Infection‐related mortality: i.e. mortality due to infection of burn wounds, sepsis, or another infective complication. </p> </li> <li> <p><b>Outcome 4:</b> Adverse events: those considered by the study investigators to be related to antibiotic prophylaxis, such as toxicity, allergies, antibiotic‐associated diarrhoea due to the overgrowth of toxigenic strains of <i>Clostridium difficile</i>, etc. </p> </li> </ul> </p> </section> <section id="CD008738-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008738-list-0003"> <li> <p><b>Outcome 5:</b> Objective measures of wound healing rate: such as time to complete healing; proportion of wounds completely healed within a trial period; proportion of participants with completely healed wounds; or proportion of wounds partly healed in a specified time period. </p> </li> <li> <p><b>Outcome 6:</b> Antibiotic resistance: defined as the clinical infection or colonisation caused by bacteria resistant to one or more antibiotics (see <a href="#CD008738-sec-0235">Differences between protocol and review</a>). </p> </li> <li> <p><b>Outcome 7:</b> All‐cause mortality: we tried to analyse this outcome according to the longest common time point of assessment among the included studies. </p> </li> <li> <p><b>Outcome 8:</b> Length of hospital stay (LOS). </p> </li> </ul> </p> <p>Studies were eligible for inclusion even if they only reported secondary outcomes, as these outcomes are relevant to patients. </p> </section> </section> </section> <section id="CD008738-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008738-sec-0051"> <h4 class="title">Electronic searches</h4> <p>In January 2013 we searched the following electronic databases to find reports of relevant RCTs: </p> <p> <ul id="CD008738-list-0004"> <li> <p>The Cochrane Wounds Group Specialised Register (searched 25 January 2013);</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) ‐ (The Cochrane Library 2012, Issue 12); </p> </li> <li> <p>Ovid MEDLINE ‐ 1950 to January Week 3 2013;</p> </li> <li> <p>Ovid MEDLINE ‐ In‐Process &amp; Other Non‐Indexed Citations, January 23, 2013;</p> </li> <li> <p>Ovid EMBASE ‐ 1980 to 2013 Week 03;</p> </li> <li> <p>EBSCO CINAHL ‐ 1982 to 25 January 2013.</p> </li> </ul> </p> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) using the following exploded MeSH headings and keywords: </p> <p>#1 MeSH descriptor Burns explode all trees<br/> #2 (burn or burns or burned or scald*):ti,ab,kw<br/> #3 (thermal NEXT injur*):ti,ab,kw<br/> #4 (#1 OR #2 OR #3)<br/> #5 MeSH descriptor Anti‐Bacterial Agents explode all trees<br/> #6 MeSH descriptor Anti‐Infective Agents, Local explode all trees<br/> #7 (antibiotic* or amoxicillin or ampicillin* or bacitracin or cephalothin or cefazolin or  cefotaxime or cefoperazone or ceftazidime or ceftriaxone or cefuroxime or chloramphenicol or ciprofloxacin or clarithromycin or clindamycin or cloxacillin or colistin or colymycin or erythromycin or flucloxacillin or furazolidone or "fusidic acid" or gentamicin or  gramicidin or imipenem or "mafenide acetate"  or mupirocin or natamycin or neomycin or  nitrofurazone or oxacillin or penicillin or piperacillin or polymyxin or rifam* or "silver  nitrate" or "silver sulfadiazine"  or "sulfacetamide sodium" or tobramycin or amphotericin  or tazocin or teicoplanin or tetracylcin or (trimethopri* NEXT sulfamethoxazole) or vancomycin):ti,ab,kw<br/> #8 (#5 OR #6 OR #7)<br/> #9 (#4 AND #8) </p> <p>The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in <a href="./appendices#CD008738-sec-0202">Appendix 1</a>. The Ovid MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximizing version (2008 revision) (<a href="./references#CD008738-bbs2-0101" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (<a href="./references#CD008738-bbs2-0127" title="Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 8 June 2011). ">SIGN 2011</a>). There were no restrictions with respect to language, date of publication or study setting. </p> <p>We searched in the following trials registers using the keywords: prophylaxis, antibiotic, and burn: </p> <p> <ul id="CD008738-list-0005"> <li> <p>International Standard Randomized Controlled Trial Number Register (http://www.controlled‐trials.com/isrctn/) (last searched May 2012); </p> </li> <li> <p>US National Institutes of Health trial registry (http://www.clinicaltrials.gov) (last searched May 2012). </p> </li> </ul> </p> </section> <section id="CD008738-sec-0052"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of all identified studies to find any further relevant trials. </p> </section> </section> <section id="CD008738-sec-0053"> <h3 class="title" id="CD008738-sec-0053">Data collection and analysis</h3> <section id="CD008738-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LB and CJ) independently assessed all titles and abstracts of studies identified by the search strategy against the eligibility criteria in terms of their relevance and design. The full text versions of all potentially eligible studies were retrieved, and the two review authors independently assessed the eligibility of each study against the inclusion criteria. </p> <p>The table of excluded studies provides details of all studies that appeared initially to meet our inclusion criteria, but which on closer examination did not, with the reasons for their exclusions. Any disagreements were resolved through discussion by the two review authors. Disagreements that could not easily be resolved were referred to a third review author (JL). </p> </section> <section id="CD008738-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>Data from the studies were extracted independently by two review authors (LB and CJ) using standardised forms. Details of included trials were extracted and summarised using a data extraction sheet. Data from trials published in duplicate were included only once, but maximal data extracted. All discrepancies were resolved by consensus among the review authors. When information within trial reports was not clear, we attempted to contact authors of the trial reports to request further details. </p> <p>We extracted the following data:</p> <p> <ul id="CD008738-list-0006"> <li> <p>Characteristics of the trial: study design, setting/location, country, period of study, method of randomisation, allocation concealment, blinding, unit of randomisation, unit of analysis, sample size calculation, use of Intention‐to‐treat analysis. </p> </li> <li> <p>Participants: number, randomised, excluded (post‐randomisation), reasons for exclusion, participants assessed, withdrawals, reasons for withdrawals, age, gender, inclusion criteria, exclusion criteria, burned surface (% of total body surface area), full‐thickness burns, inhalation injury, time post‐burn, burn type, the state of the wounds at baseline, co‐morbidities. </p> </li> <li> <p>Type of intervention: intervention group: antibiotic, dose, route, frequency, duration of treatment, co‐interventions. Control group: description of the intervention applied (if any). </p> </li> <li> <p>Outcome data.</p> </li> <li> <p>Source of funding, conflicts of interest.</p> </li> </ul> </p> <p>Data were entered into Review Manager by one review author (LB) (<a href="./references#CD008738-bbs2-0121" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.1.. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 22 March 2011. ">RevMan 2011</a>), and double checked by a second review author (JL). </p> </section> <section id="CD008738-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LB and CJ) independently assessed the risk of bias of each included study using the criteria outlined in the tool designed by the Cochrane Collaboration (<a href="./references#CD008738-bbs2-0092" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>) (see <a href="#CD008738-sec-0235">Differences between protocol and review</a>). We considered the following domains: </p> <p> <ol id="CD008738-list-0007"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding for participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).  </p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective outcome reporting (reporting bias).</p> </li> <li> <p>Other sources of bias (considered in combination, that is, if at least one of these other sources of bias is considered to be 'high', this domain will be judged as 'high'): </p> <ol id="CD008738-list-0008"> <li> <p>for cluster‐randomised trials, we assessed these additional sources of bias: recruitment bias; baseline imbalance either across clusters or patients; loss of clusters and incorrect analysis (<a href="./references#CD008738-bbs2-0093" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>, Section 16.3.2); </p> </li> <li> <p>for the trials where the unit of randomisation was the patient, we also assessed whether there were similar baseline characteristics between the study groups; </p> </li> <li> <p>for all the included studies we also assessed whether there were baseline imbalances in factors that are strongly related to outcome measures, whether the analysis of time‐to‐event data was adequate, whether the study was stopped early due to some data‐dependent process, and whether there was any declared financial support. </p> </li> </ol> </li> </ol> </p> <p>We made assessments for each main outcome (or class of outcomes).<b> </b>We labelled each criterion as being at 'low ', 'high' or 'unclear' risk of bias. See <a href="./appendices#CD008738-sec-0203">Appendix 2</a> for details of criteria on which the judgements were based. We tried to obtain this information from the trial reports, but, when there was not enough information to make a judgement, we wrote to the trial authors for clarification. Disagreements were resolved by discussion and consensus. We included two figures in the review: a 'Risk of bias graph figure' (<a href="#CD008738-fig-0001">Figure 1</a>) and a ‘Risk of bias summary figure’ (<a href="#CD008738-fig-0002">Figure 2</a>). We assessed the overall risk of bias for each outcome (or class of similar outcomes) within each study. Each outcome (or class of outcomes) was defined as having a ‘low risk of bias’ only if it was at low risk of bias for all the domains; at ‘high risk of bias’ if it demonstrated high risk of bias for one or more of the domains; or at ‘unclear risk of bias’ if it demonstrated unclear risk of bias for at least one domain without any of the other domains being described as ‘high risk of bias’. </p> <div class="figure" id="CD008738-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008738-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008738-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008738-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Finally, we incorporated the results of the risk of bias assessment into the review through systematic narrative description and commentary and we explored the effect of the risk of bias in the meta‐analysis by carrying out sensitivity analysis (see <a href="#CD008738-sec-0096">Effects of interventions</a>). </p> </section> <section id="CD008738-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <p>We reported the risk ratio (RR) for dichotomous data (e.g. incidence of participants with infection), mean difference (MD) for continuous data (e.g. length of hospital stay) and hazard ratios (HR) for time‐to‐event data (e.g. time to healing) . All outcome effects are shown with their associated 95% confidence intervals (CI). </p> </section> <section id="CD008738-sec-0058"> <h4 class="title">Unit of analysis issues</h4> <p>Although we did not expect that unit of analysis issues would arise in many eligible studies, a variety of them were found, including: </p> <p> <ol id="CD008738-list-0009"> <li> <p>some trials reported on a per patient basis and other trials on a per burn basis; and </p> </li> <li> <p>self‐controlled studies varied in the level where randomisation was done (some trials randomised adjacent wounds from the same arm or body part; others randomised non adjacent wounds from different parts of the body). </p> </li> </ol> </p> <p>Effect measures adjusted by design were computed for these trials, namely Becker‐Balagtas odds ratios and corresponding confidence intervals (<a href="./references#CD008738-bbs2-0083" title="CurtinF , ElbourneD , AltmanDG . Meta‐analysis combining parallel and cross‐over clinical trials. II: Binary outcomes. Statistics in Medicine2002;21(5):2145‐59. ">Curtin 2002</a>). These trials provided data for the outcomes 'burn wound infection' and 'adverse effects', that were defined as generalized‐inverse variance in order to accommodate effect measures for both parallel and self‐controlled trials. The effect measures considered were either Mantel‐Haenzsel odds ratios, for parallel design trials, or Becker‐Balagtas odds ratios, for self‐controlled trials. </p> </section> <section id="CD008738-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>We assessed and reported on missing outcome data for the included studies and contacted the authors of the primary studies where necessary (if we did not obtain this data, we documented this on the data extraction form and in the text of the review). </p> <p>We carried out analyses on an intention‐to‐treat basis for all outcomes (i.e. to include all participants randomised to each group in the analyses, irrespective of what happened subsequently). There were some studies, however, that included participants whose outcomes were unknown. In these cases, we performed an ‘available case analysis’, where data are analysed for participants for whom outcome data were obtained. </p> <p>We explored the impact on the overall treatment effect of missing data (&gt;20% of for overall trial population or any trial arm) by using a worst‐case scenario sensitivity analysis (missing participants experienced a negative dichotomous outcome) (<a href="#CD008738-sec-0064">Sensitivity analysis</a>)(see <a href="#CD008738-sec-0235">Differences between protocol and review</a>). </p> </section> <section id="CD008738-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>Where possible we displayed the results of clinically and methodologically comparable studies graphically and assessed heterogeneity visually. We assessed heterogeneity between study results using the I² statistic (<a href="./references#CD008738-bbs2-0091" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>) This examines the percentage of total variation across studies due to heterogeneity rather than chance. We judged the importance of the observed value of I² depending on the magnitude and direction of effects and the strength of evidence for heterogeneity (moderate to high heterogeneity will be defined as I² greater than, or equal to, 50%) (<a href="./references#CD008738-bbs2-0085" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD008738-sec-0061"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias by means of a funnel plot for each outcome (a simple scatter plot of the intervention effect estimates from individual studies against some measure of each study’s size or precision (<a href="./references#CD008738-bbs2-0130" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Sterne 2011</a>)). Funnel plot asymmetry would be assessed statistically. If there was evidence of asymmetry, publication bias would be considered as only one of a number of possible explanations. </p> </section> <section id="CD008738-sec-0062"> <h4 class="title">Data synthesis</h4> <p>Where sufficient numbers of comparable studies were available these were combined in a meta‐analysis to produce pooled RR for dichotomous data (e.g. incidence of peoples with infection), MD for continuous data (e.g. length of hospital stay (LOS)) and HR for time‐to‐event data (e.g. time to healing), with 95% CIs . We report outcome measurements for six different types of antibiotic prophylaxis addressed in the included trials. </p> <p>When there were results from different follow‐up points within the same study, we considered shorter follow‐up periods for the meta‐analysis. We made this decision on the grounds that it was more likely that we would obtain measurements over a short period. Results for subsequent follow‐up periods were presented in narrative form only. For the outcome 'all‐cause mortality' we considered results concerning the end of the follow‐up period. We used a random‐effects model to pool data, although we assessed by means of a sensitivity analysis the influence of a fixed‐effect model. In the event that relevant statistical heterogeneity was detected (I² greater than, or equal to, 50%), or if the meta‐analysis was inappropriate for any other reason, we presented a narrative analysis of eligible studies, providing a descriptive presentation of the results, grouped by intervention and study design, with supporting tables. All outcome effects were shown with their associated 95% confidence intervals (CI). </p> <p>We performed the analyses using Review Manager 5.1 (<a href="./references#CD008738-bbs2-0121" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.1.. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 22 March 2011. ">RevMan 2011</a>), the statistical package provided by the Cochrane Collaboration. </p> </section> <section id="CD008738-sec-0063"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out subgroup analyses:</p> <p> <ul id="CD008738-list-0010"> <li> <p>age of participants: children (aged between 0 and 18 years) compared with adults (over18 years); and, </p> </li> <li> <p>severity of burn: burns involving less than 20% total body surface area (TBSA) versus burns involving more than 20% TBSA. </p> </li> </ul> </p> <p>It was not possible to perform these subgroup analyses, however, because of the paucity of studies providing the necessary data. </p> </section> <section id="CD008738-sec-0064"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to assess for:</p> <p> <ol id="CD008738-list-0011"> <li> <p>The effect of including studies with high or unclear risk of bias (as defined above), by excluding these trials from a comparative analysis. </p> </li> <li> <p>The effect of missing data, by performing a comparative analysis excluding studies with high levels of missing data (more than 20% of missing data for the overall trial population, or for any of the trial arms) ). </p> </li> <li> <p>The impact of withdrawals, by performing a comparative analysis (per protocol analysis 'available case analysis' and intention‐to‐treat analysis). We also performed a worst case scenario sensitivity analysis (considering missing data as negative events). </p> </li> <li> <p>The effect of the allocation/analysis unit (burn wounds or patients) by performing a comparative analysis restricted to self‐controlled studies (<i>post hoc</i> sensitivity analysis). </p> </li> </ol> </p> <p>All other analyses planned in the protocol were not performed for a variety of reasons, see '<a href="#CD008738-sec-0235">Differences between protocol and review</a>' for details. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008738-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008738-sec-0065"></div> <section id="CD008738-sec-0066"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD008738-sec-0238" title="">Characteristics of included studies</a>; <a href="./references#CD008738-sec-0239" title="">Characteristics of excluded studies</a>; <a href="./references#CD008738-sec-0240" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD008738-sec-0067"> <h4 class="title">Results of the search</h4> <p>Searches for this review yielded 835 references. After eliminating duplicates, two review authors (LB and CJ) independently assessed the identified references against the inclusion criteria. During the scrutiny of titles and abstracts we identified 72 potentially‐relevant references, and the full text of each was retrieved. Of these, two articles have been designated as awaiting classification whilst contact with the trial author is made in order to obtain further information (<a href="./references#CD008738-bbs2-0070" title="MaghsoudiH , SalehiF , KhosrowshahiMK , BaghaeiM , NasirzadehM , ShamsR . Comparison between topical honey and mafenide acetate in treatment of burn wounds. Annals of Burns and Fire Disasters 2011;24(3):132‐7. ">Maghsoudi 2011</a>; <a href="./references#CD008738-bbs2-0071" title="PanahiY , BeiraghdarF , AkbariH , BekhradiH , TaghizadehM , SahebkarA . A herbal cream consisting of Aloe vera, Lavandulastoechas, and Pelargonium roseum as an alternative for silver sulfadiazine in burn management. Asian Biomedicine2012;6(2):273‐8. ">Panahi 2012</a>) Thirty six studies (37 publications) met the inclusion criteria for this review (information on methods, participants, interventions, and outcomes of each one of these trials can be found in the <a href="./references#CD008738-sec-0238" title="">Characteristics of included studies</a> table). The search strategy identified one duplicate publication (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>). See <a href="#CD008738-fig-0003">Figure 3</a> flow diagram. </p> <div class="figure" id="CD008738-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD008738-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> <section id="CD008738-sec-0068"> <h5 class="title">Excluded studies</h5> <p>The <a href="./references#CD008738-sec-0239" title="">Characteristics of excluded studies</a> table provides reasons for the exclusion of each study. Nine studies were quasi‐randomised (<a href="./references#CD008738-bbs2-0043" title="CasonJS , JacksonDM , LowburyEJL , RickettsCR . Antiseptic and aseptic prophylaxis for burns: use of silver nitrate and of isolators. British Medical Journal1966;2(5525):1288‐94. ">Cason 1966</a>; <a href="./references#CD008738-bbs2-0045" title="DeutschDH , MillerSF , FinleyRK . The use of intestinal antibiotics to delay or prevent infections in patients with burns. Journal of Burn Care and Rehabilitation1990;11(5):436‐42. ">Deutsch 1990</a>; <a href="./references#CD008738-bbs2-0051" title="HunterGR , ChangFC . Outpatient burns: a prospective study. Journal of Trauma1976;16(3):191‐5. ">Hunter 1976</a>; <a href="./references#CD008738-bbs2-0054" title="LowburyEJ ,  JacksonDM . Local chemoprophylaxis for burns with gentamicin and other agents. Lancet1968;1(7544):654‐7. ">Lowbury 1968</a>; <a href="./references#CD008738-bbs2-0055" title="MalikKI , MalikMA , AslamA . Honey compared with silver sulphadiazine in the treatment of superficial partial‐thickness burns. International Wound Journal 2010;7(5):413‐7. ">Malik 2010</a>; <a href="./references#CD008738-bbs2-0056" title="ManuskiattiW , FitzpatrickRE , GoldmanMP , Krejci‐PapaN . Prophylactic antibiotics in patients undergoing laser resurfacing of the skin. Journal of the American Academy of Dermatology1999;40(1):77‐84. ">Manuskiatti 1999</a>; <a href="./references#CD008738-bbs2-0059" title="MunsterAM , XiaoGX , GuoY , WongLA , WinchurchRA . Control of endotoxemia in burn patients by use of polymyxin B. Journal of Burn Care and Rehabilitation1989;10(4):327‐30. ">Munster 1989</a>; <a href="./references#CD008738-bbs2-0063" title="ProctorDS . The treatment of burns: a comparative trial of antibiotic dressings. South African Medical Journal1971;45(2):231‐6. ">Proctor 1971</a>; <a href="./references#CD008738-bbs2-0069" title="WaffleC , SimonRR , JoslinC . Moisture‐vapour‐permeable film as an outpatient burn dressing. Burns, Including Thermal Injury 1988;14(1):66‐70. ">Waffle 1988</a>). Three studies did not evaluate any of the review outcomes (<a href="./references#CD008738-bbs2-0039" title="AhujaRB , GuptaA , GurR . A prospective double‐blinded comparative analysis of framycetin and silver sulphadiazine as topical agents for burns: A pilot study. Burns2009;35(5):672‐6. ">Ahuja 2009</a>; <a href="./references#CD008738-bbs2-0057" title="MashhoodAA , KhanTA , SamiAN . Honey compared with 1% silver sulfadiazine cream in the treatment of superficial and partial thickness burns. Journal of Pakistan Association of Dermatologists 2006;16(1):14‐9. ">Mashhood 2006</a>; <a href="./references#CD008738-bbs2-0068" title="VarasRP , O'KeeffeT , NamiasN , PizanoLR , QuintanaOD , Herrero TellacheaM , et al. A prospective, randomized trial of Acticoat versus silver sulfadiazine in the treatment of partial‐thickness burns: which method is less painful?. Journal of Burn Care and Rehabilitation2005;26(4):344‐7. ">Varas 2005</a>). In nine studies, the interventions did not allow evaluation of the effectiveness of the antibiotic because the antibiotic was given in both arms of the study (i.e. topical silver sulfadiazine (SSD) alone versus SSD combined with cerium nitrate (SSD–CN); 1% silver sulfadiazine plus 0.2% chlorhexidine digluconate cream versus 1% silver sulfadiazine) (<a href="./references#CD008738-bbs2-0037" title="Abdel‐RazekSM , Abdel‐KhalekAH , AllamAM , ShalabyH , MandoorS , HigaziM . Impact of selective gastrointestinal decontamination on mortality and morbidity in severely burned patients. Annals of Burns and Fire Disasters2000;XIII(4):1‐5. ">Abdel‐Razek 2000</a>; <a href="./references#CD008738-bbs2-0041" title="BranskiLK , HerndonDN , CelisMM , NorburyWB , MastersOE , JeschkeMG . Amnion in the treatment of pediatric partial‐thickness facial burns. Burns2008;34(3):393‐9. ">Branski 2008</a>; <a href="./references#CD008738-bbs2-0044" title="DeGraciaCG . An open study comparing topical silver sulfadiazine and topical silver sulfadiazine‐cerium nitrate in the treatment of moderate and severe burns. Burns2001;27(1):67‐74. ">De Gracia 2001</a>; <a href="./references#CD008738-bbs2-0046" title="DonatiL , PeritiP . Antibiotic treatment of burned patients: an Italian multicentre study. Intensive Care Medicine1994;20(Suppl 4):S30‐4. ">Donati 1994</a>; <a href="./references#CD008738-bbs2-0047" title="FangCH , NathanP , RobbEC , AlexanderJW , MacMillanBG . Prospective clinical study of Hydron, a synthetic dressing, in delivery of an antimicrobial drug to second‐degree burns. Journal of Burn Care and Rehabilitation 1987;8(3):206‐9. ">Fang 1987</a>; <a href="./references#CD008738-bbs2-0052" title="InmanRJ , SnellingCF , RobertsFJ , ShawK , BoyleJC . Prospective comparison of silver sulfadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent (Silvazine) and silver sulfadiazine 1 per cent (Flamazine) as prophylaxis against burn wound infection. Burns, Including Thermal Injury 1984;11(1):35‐40. ">Inman 1984</a>; <a href="./references#CD008738-bbs2-0058" title="MillerL , HansbroughJ , SlaterH , GoldfarbIW , KealeyP , SaffleJ , et al. Sildimac: a new delivery system for silver sulfadiazine in the treatment of full‐thickness burn injuries. Journal of Burn Care and Rehabilitation 1990;11(1):35‐41. ">Miller 1990</a>; <a href="./references#CD008738-bbs2-0060" title="OenIM ,  van BaarME ,  MiddelkoopE ,  NieuwenhuisMK . Facial Burns Group. Effectiveness of cerium nitrate‐silver sulfadiazine in the treatment of facial burns: a multicenter, randomized,controlled trial. Plastic and Reconstructive Surgery2012;130(2):274e‐283e. ">Oen 2012</a>; Ostile 2012). Seven trials were excluded either because the wounds were already infected, or because they involved residual burn wounds (<a href="./references#CD008738-bbs2-0040" title="BaghelPS ,  ShuklaS ,  MathurRK ,  RandaR . A comparative study to evaluate the effect of honey dressing and silver sulfadiazene dressing on wound healing in burn patients. Indian Journal of Plastic Surgery2009;42(2):176‐81. ">Baghel 2009</a>; <a href="./references#CD008738-bbs2-0042" title="CarneiroPM , RwanyumaLR , MkonyCA . A comparison of topical Phenytoin with Silverex in the treatment of superficial dermal burn wounds. Central African Journal of Medicine2002;48(9‐10):105‐8. ">Carneiro 2002</a>; <a href="./references#CD008738-bbs2-0049" title="HuangYS , LiXL , LiaoZJ , ZhangGA , LiuQ , TangJ , et al. Multi‐center clinical study of acticoat (nanocrystalline silver dressing) for the management of residual burn wounds: Summary report. Zhonghua Shao Shang Za Zhi2006;22(1):15‐8. ">Huang 2006</a>; <a href="./references#CD008738-bbs2-0050" title="HuangY , LiX , LiaoZ , ZhangG , LiuQ , TangJ , et al. A randomized comparative trial between Acticoat and SD‐Ag in the treatment of residual burn wounds, including safety analysis. Burns2007;33(2):161‐6. ">Huang 2007</a>; <a href="./references#CD008738-bbs2-0053" title="LiXL , HuangYS , PengYZ , LiaoZJ , ZhangGA , LiuQ , et al. Multi‐center clinical study of acticoat (nanocrystalline silver dressing) for the management of residual burn wounds. Zhonghua Shao Shang Za Zhi2006;22(1):15‐8. ">Li XL 2006</a>; <a href="./references#CD008738-bbs2-0064" title="RamosG , RestaM , Machare DelgadoE , DurlachR , Fernandez CanigiaL , BenaimF . Systemic perioperative antibiotic prophylaxis may improve skin autograft survival in patients with acute burns. Journal of Burn Care and Research2008;29(6):917‐23. ">Ramos 2008</a>; <a href="./references#CD008738-bbs2-0066" title="SubrahmanyamM . Topical application of honey in treatment of burns. British Journal of Surgery1991;78(4):497‐8. ">Subrahmanyam 1991</a>); five studies did not provide information that could be used for our review (<a href="./references#CD008738-bbs2-0038" title="AfilaloM , DankoffJ , GuttmanA , LloydJ . DuoDERM hydroactive dressing versus silver sulphadiazine/Bactigras in the emergency treatment of partial skin thickness burns. Burns1992;18(4):313‐6. ">Afilalo 1992</a>; <a href="./references#CD008738-bbs2-0048" title="GrippaudoFR , CariniL , BaldiniR . Procutase versus 1% silver sulphadiazine in the treatment of minor burns. Burns2010;36(6):871‐5. ">Grippaudo 2010</a>; <a href="./references#CD008738-bbs2-0062" title="PielP , ScarnatiS , GoldfarbIW , SlaterH . Antibiotic prophylaxis in patients undergoing burn wound excision. Journal of Burn Care and Rehabilitation1985;6(5):422‐4. ">Piel 1985</a>; <a href="./references#CD008738-bbs2-0065" title="SteerJA , PapiniRP , WilsonAP , McGroutherDA , NakhlaLS , ParkhouseN . Randomized placebo‐controlled trial of teicoplanin in the antibiotic prophylaxis of infection following manipulation of burn wounds. British Journal of Surgery1997;84(6):848‐53. ">Steer 1997</a>; <a href="./references#CD008738-bbs2-0067" title="UgburoAO , AtoyebiOA , OyeneyinJO , SowemimoGO . An evaluation of the role of systemic antibiotic prophylaxis in the control of burn wound infection at the Lagos University Teaching Hospital. Burns2004;30(1):43‐8. ">Ugburo 2004</a>). </p> </section> </section> <section id="CD008738-sec-0069"> <h4 class="title">Included studies</h4> <p>This review included a total of 36 trials, published between September 1968 and July 2010. Thirty‐four articles were published in English, one in German (<a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>), one in Spanish (<a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>) and one in Chinese (<a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>). Fifteen studies included adult and paediatric participants (<a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>); 11 included only adults (<a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; Silver 2007; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>), and 10 included only children (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). </p> <section id="CD008738-sec-0070"> <h5 class="title">Study country</h5> <p>Twenty trials were conducted in the USA (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>), four in Iran (<a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>), two in China (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>), and two in India (<a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). There was one trial that did not specify the country or region where the study took place (<a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>). The remaining seven trials were conducted in Switzerland, Spain, South Africa, Germany, Japan, Mexico and Thailand (<a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>). </p> </section> <section id="CD008738-sec-0071"> <h5 class="title">Setting</h5> <p>Trials were conducted in emergency departments (<a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>), operating rooms (<a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>), intensive care units (<a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>), ambulatory care units (<a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>) or burns care facilities (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>). For twelve trials there was no specific information about the place where the trial took place, but the trial authors did mention that the trials were conducted in a hospital setting (<a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). </p> </section> <section id="CD008738-sec-0072"> <h5 class="title">Sample size</h5> <p>Four trials reported a sample size calculation (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>). The size of the studies varied between 14 and 249 participants, with a total of 2117 participants included in the review. Only eleven trials (30%) included more than 70 participants (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>). </p> </section> <section id="CD008738-sec-0073"> <h5 class="title">Unit allocation</h5> <p>In 30 trials (83%) the unit of allocation was the individual participant (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>, <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). In the six remaining trials, the unit of allocation was the wound, with each participant serving as his, or her, own control (<a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). Matched wounds in the same participant (areas with similar burns) were randomised to both modalities of treatment (see <a href="#CD008738-sec-0058">Unit of analysis issues</a> and <a href="#CD008738-sec-0086">Allocation (selection bias)</a>). </p> <p>The analysis of six studies included in the review, however, did not take into account the level at which randomisation occurred (thus incurring '<a href="#CD008738-sec-0058">Unit of analysis issues</a>`) (<a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>): </p> <p> <ul id="CD008738-list-0012"> <li> <p>Two trials mostly randomised a single burn for each participant (<a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>), but included some data for different burns in some participants. These trials randomised 43 and 52 participants, and analysed 50 and 56 burns, respectively. The degree of correlation introduced was considered to be low. </p> </li> <li> <p>Four trials randomised different parts of the body to receive different interventions (<a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>), that is, for each participant two different burn wounds were randomised to either the treatment or to the control group. These trials provided data for outcomes such as 'burn wound infection' and 'adverse effects', that were analyzed as described in <a href="#CD008738-sec-0058">Unit of analysis issues</a>. </p> </li> </ul> </p> <section id="CD008738-sec-0074"> <h6 class="title">Economic support</h6> <p>Eight trials reported that they had received economic support from pharmaceutical companies, foundations, or public institutions (<a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>). One trial reported that authors had not received any economic support (<a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>), while the remaining 29 articles did not report any information on this matter. </p> </section> <section id="CD008738-sec-0075"> <h6 class="title">Conflicts of interest</h6> <p>Only three trials reported potential conflicts of interest (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>). In the <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a> study, one of the authors worked with financial support from BG‐Kliniken Bergmannsheil Bochum and Mundipharma, who also provided some of the medications used in the study. The authors highlighted that, despite the potential conflict of interest, they had conducted the trial in an independent manner. Foundations and public institutions supported four trials (<a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>). There was no information about sources of funding for the remaining studies. None of the included studies was judged to be at high risk of bias due to funding. </p> </section> </section> <section id="CD008738-sec-0076"> <h5 class="title"><i>Characteristics of the burn wounds</i> </h5> <section id="CD008738-sec-0077"> <h6 class="title">Source of burn</h6> <p>Fourteen studies included participants with burns caused by a variety of sources: fire, hot liquids (scalds), hot solids (contact burns), electrical, chemical and other agents (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). Seven studies included participants with burns caused by fire and hot liquids (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). Three studies included participants with burns caused exclusively by fire (<a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>), and two studies included participants with burns caused exclusively by hot liquids (<a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>). Ten studies did not specify the source of the burn (<a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>). </p> </section> <section id="CD008738-sec-0078"> <h6 class="title">Thickness</h6> <p>Partial‐thickness and superficial burns were the most prevalent types of burn and featured in 27 studies (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>, <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>), followed by full‐thickness burns in five studies (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>). Four studies did not describe the thickness of burns (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>). </p> </section> <section id="CD008738-sec-0079"> <h6 class="title">Burned surface</h6> <p>There was considerable variation among studies regarding the size of the reported burn area in terms of total body surface area (TBSA) which varied from one percent to 91% (average values per group). </p> </section> <section id="CD008738-sec-0080"> <h6 class="title">Time post‐burn</h6> <p>Twelve trials included people with burns acquired less than 24 hours earlier at the time of enrolment in the study (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). In the remaining trials, limits were: less than 36 hours (<a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>), 48 hours (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>), 72 hours (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>), four days (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>), and six days (<a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>). Fifteen trials did not provide this information (<a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). </p> </section> </section> <section id="CD008738-sec-0081"> <h5 class="title">Type of antibiotic prophylaxis evaluated</h5> <p>The studies evaluated the following types of antibiotic prophylaxis:</p> <p><b>1. Topical antibiotic prophylaxis (26 trials)</b> </p> <p> <ul id="CD008738-list-0013"> <li> <p>Comparison 1: neomycin, bacitracin, and polymyxin B versus inactive control (no intervention or placebo). </p> </li> <li> <p>Comparison 2: silver sulfadiazine (SSD) versus polymyxin B/bacitracin.</p> </li> <li> <p>Comparison 3: SSD versus dressings or skin substitutes.</p> </li> <li> <p>Comparison 4: SSD versus any topical preparation of natural products (traditional medicine). </p> </li> <li> <p>Comparison 5: other topical antibiotics versus dressings or skin substitutes.</p> </li> <li> <p>Comparison 6: antibiotic prophylaxis versus other treatments.</p> </li> </ul> </p> <p><b>2. Systemic antibiotic prophylaxis (general) (3 trials)</b> </p> <p><b>3. Systemic antibiotic prophylaxis (perioperative) (4 trials)</b> </p> <p> <ul id="CD008738-list-0014"> <li> <p>Comparison 1: antibiotic prophylaxis versus control/placebo.</p> </li> <li> <p>Comparison 2: cephazolin versus another antibiotic.</p> </li> </ul> </p> <p><b>4. Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract (SDD)) (2 trials)</b> </p> <p> <ul id="CD008738-list-0015"> <li> <p>Comparison 1: non‐absorbable antibiotic prophylaxis versus placebo.</p> </li> <li> <p>Comparison 2: non‐absorbable antibiotic prophylaxis and cefotaxime versus placebo.</p> </li> </ul> </p> <p><b>5. Local antibiotic prophylaxis (administered by airway) (1 trial)</b> </p> </section> <section id="CD008738-sec-0082"> <h5 class="title">Outcomes reported</h5> <section id="CD008738-sec-0083"> <h6 class="title">Primary outcomes</h6> <p>With the exception of four trials (<a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>), all trials reported on the frequency of burn wound infection, however, the definitions of infection and the methods of diagnosis were heterogeneous. Five trials (14%) defined burn wound infection as the presence of over 10<sup>5</sup> organisms per gram of tissue (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>); 10 trials (28%) accepted a positive bacterial culture of wound samples as proof of infection (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>); 11 trials (30%) determined burn wound infection through the clinic evaluation of signs and symptoms (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>), while six trials (17%) did not define burn wound infection (<a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>). </p> <p>In 14 trials (39%) information was provided about other types of infection present in the burned person, specifically pneumonia, urinary tract Infection, bacteraemia, and sepsis (<a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>); definitions for each of these can be found in <a href="#CD008738-tbl-0001">Table 1</a>. </p> <div class="table" id="CD008738-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Definition of the outcomes assessed</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study‐Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Wound infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sepsis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Bacteraemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Pneumonia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Urinary tract infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Adverse events </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Time to complete healing </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discharge of pus in the graft site, associated with graft loss.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event related to the administration of the antibiotic or the placebo. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define bacteraemia, but assessed the total number of episodes of bacteraemia per days at risk </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical evaluation (presence of fever and/or redness of the wound) and qualitative bacteriological examination of samples from the wound. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bacterial infection was evaluated by bacteriological examination of blood.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of respiratory infection was determined by qualitative bacteriological examination of sputum. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined the presence of urinary tract infection by qualitative bacteriological examination of urine. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wound was declared healed when 75% of the total surface had healed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined BWI through the assessment of clinical data.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define bacteraemia, but reported data on this result.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined wound cicatrisation as closing of all affected areas in the initial wound.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burn wound biopsy with more than 10<sup>5</sup> organism/g<br/> tissue and/or histologic evidence of viable tissue<br/> invasion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of a septic source: (1) burn wound biopsy with more than 10<sup>5</sup> organism/g<br/> tissue and/or histologic evidence of viable tissue<br/> invasion, (2) positive blood culture, (3) urinary tract infection with 10<sup>5</sup> organism/ml urine; and (4) pulmonary infection with positive bacteria and white<br/> cells on a class III, or better sputum specimen. </p> <p>In addition to the identification of a septic source, five or more of the following criteria had to be met: tachypnoea<br/> (&gt; 40 breaths/minute); prolonged paralytic ileus;<br/> hyper‐ or hypothermia (&lt; 36.5°C or &gt; 38.5°C); altered<br/> mental status; thrombocytopenia (&lt; 50 000 platelets/mm<sup>3</sup>); leucocytosis or leukopenia (&lt; 3.5 or &gt; 15.0 cells/mm<sup>3</sup>); unexplained acidosis; or hyperglycaemia. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary infection with positive bacteria and white<br/> cells on a class III, or better sputum specimen. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but registered diverse complication.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported time to complete healing.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this result.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported allergies and bleeding as adverse events.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A wound was considered cicatrised when it had healed completely.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this result.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any new adverse event (including infection) or any adverse event that had worsened during the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A wound was considered cicatrised when there was 100% re‐epithelisation, including the small residual crusts, blisters and open areas of &lt; 1 cm in an area that had been re‐epithelialized completely.    </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI determined by microbiological testing of samples from the surface of the wound, performed upon admission and then twice a week. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bloodstream infections<br/> were diagnosed according to CDC definitions for nosocomial<br/> infections. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of new (or<br/> progressive) pulmonary infiltrates persisting for &gt; 48 h on chest X‐ray, in addition to at least 2 of the following<br/> criteria: (1) fever ≥ 38.5°C or hypothermia &lt; 35.0°C; (2) leucocytosis ≥ 10,000/mm<sup>3</sup> or leukopenia &lt; 3000/mm<sup>3</sup>;<br/> (3) isolation of potential pathogens in high concentration of<br/> ≥ 4 x 10<sup>7</sup> cfu/ml using semi quantitative<br/> culture, from unprotected purulent tracheal aspirates. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary tract infections<br/> were diagnosed according to CDC definitions for nosocomial<br/> infections. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI determined by clinical assessment of signs (increased exudate and surrounding cellulitis). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the wounds were healed when re‐epithelialization had reached ≥ 90%.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Accepted quantitative culture of samples from the wound as evidence of infection.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the wounds were healed when re‐epithelialization had reached 95%.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined BWI through the clinical evaluation of signs and symptoms.  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wound infection was considered when had cellulitis. The cellulitis was clinically defined as an area of warm, spreading, cutaneous erythema, accompanied by local pain and fever. Cellulite was determined by positive culture of samples from the surface of the wound. </p> <p>The samples for the culture were taken upon admission, and the samples for follow‐up, at days 5 and 7.  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syndrome resulting from the presence<br/> of &gt; 100,000 organisms/g biopsied wound tissue, associated with variable temperature and<br/> leucocyte count, blood chemistry abnormalities, and occasionally ‐ but not invariably ‐ accompanied by positive blood cultures. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define bacteraemia, but reported data on bacteraemia by beta‐haemolytic streptococcal.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define urinary tract infection, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the presence of "local purulence" constituted infection. Additionally, accepted a positive bacterial culture of wound samples as proof of infection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define the term sepsis, but reported patients who had presented with purulence with septicaemia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of systemic disease.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported time to healing.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection determined by semi‐quantitative cultures of surface samples.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Completely re‐epithelialized wounds. Wounds considered to be treatment failures if had not healed within 21  days or had required skin grafts. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healing time defined as the time required to achieve full epithelialisation of the burned surface. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined BWI through the assessment of clinical data.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on possible adverse effects.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection determined by semi‐quantitative cultures of wound surface samples.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on adverse reactions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not report the definition of cicatrisation, but assessed the percentage of wound healing at different times, up to 21 days and to the time healing.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI defined by the presence of clinical data in conjunction with cultures from the wound surface. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported time to healing.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection determined by semi‐quantitative cultures of wound surface samples.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the wounds were healed when re‐epithelialization had reached 95%‐100%.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined BWI through the assessment of clinical data.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients satisfying all of the following criteria: (1) infiltration of lung fields on chest X‐ray films;<br/> (2) fever (&gt; 38°C) for at least 3 consecutive days; </p> <p>(3) peripheral<br/> white blood cell count &gt; 10<sup>4</sup>/mm<sup>3</sup>. </p> <p>(4) Pathogenic<br/> bacteria (&gt; 10<sup>3</sup> cfu/ml) detected in airway<br/> secretions. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but assessed the associated secondary effects during the period of antibiotic administration. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define urinary tract infection but reported data on this outcome.</p> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined by clinical assessment</p> <p>of the wound</p> <p>(assessment of the nature of epithelialization ‐ percentage and healing time). </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define sepsis, but reported that blood cultures were performed three times a week and upon suspicion of sepsis. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>More than 10<sup>5</sup> organisms/g of<br/> tissue in both the nonadherent graft and recipient<br/> site. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define sepsis, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI determined by daily assessment of signs and symptoms.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined wound infection as cellulitis.</p> <p>Bacterial cultures were performed when there was suspicion of infection and at the end of the study. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define pneumonia, but reported data on this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define urinary tract infection, but reported data on this outcome. Conducted routine urine analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on adverse reactions.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined wound infection through the  daily evaluation of signs and symptoms.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>When there were symptoms and signs of hypothermia,<br/> hypotension, abrupt hyperglycaemia, decreased urine output, thrombocytopenia and diet intolerance, a thorough check‐up including blood culture and urine culture was done. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported data on time to healing.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined wound infection by clinical data in conjunction with cultures from the wound surface. </p> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of clinical data together with burn wound biopsy with &gt; 10<sup>5</sup> organisms/g<br/> tissue. Biopsies were taken twice a week. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined sepsis through two parameters: (1) presence of a positive blood culture, and the presence or absence of standard signs of sepsis such as hypothermia, disorientation and paralytic ileus; or (2) presence of a quantitative biopsy on one or more occasions of ≥ 10<sup>5</sup> organisms coupled with any of the clinical parameters mentioned above. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on possible adverse effects.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that wounds were healed when there had been epithelial closing of 90% of the site of the wound. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI determined by quantitative culture of tissue biopsies. Performed colony count; results expressed as cfu/g of tissue. </p> <p>A culture was considered positive when growth was more than 10<sup>5</sup> cfu/g of tissue.  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define bacteraemia, but reported data on this outcome. Blood cultures were performed for the isolation and identification of pathogenic organisms. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on possible adverse effects.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the wounds were healed when there was a new layer of epithelium.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of burn wound biopsy with &gt; 10<sup>5</sup> organisms/g<br/> tissue. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined wound infection through the  evaluation of clinical data.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse effects related to medication (allergic or hypersensitivity reactions) or a worsening of symptoms or complications (infection, wound infection). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported data on time to healing.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations</b> </p> <p>&lt; = less than<br/> &gt; = more than<br/> ≥ = more than or equal to<br/> BWI = burn wound infection<br/> CDC = Centers for Disease Control<br/> cfu = colony forming units<br/> h = hour(s) </p> </div> </div> <p>Infection‐related mortality was reported in four trials (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>). </p> <p>Twelve trials presented information on adverse events related to antibiotic prophylaxis (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). </p> </section> <section id="CD008738-sec-0084"> <h6 class="title">Secondary outcomes</h6> <p>The most frequently reported secondary outcomes were time to complete wound healing (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>), and length of hospital stay (LOS) (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). Definitions of outcomes reported can be found in <a href="#CD008738-tbl-0001">Table 1</a>. </p> </section> </section> </section> </section> <section id="CD008738-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias is summarised in <a href="#CD008738-fig-0001">Figure 1</a> and <a href="#CD008738-fig-0002">Figure 2</a>. The Risk of bias graph (<a href="#CD008738-fig-0001">Figure 1</a>) illustrates the proportion of studies with each of the judgements (‘low risk’, 'high risk’, ‘unclear risk’ of bias) for each domain in the tool, while the Risk of bias summary (<a href="#CD008738-fig-0002">Figure 2</a>) presents all the judgements in a cross‐tabulation of study by domain. We also presented a descriptive analysis of each domain of the risk of bias tool. In total, eight trials were deemed to be at unclear risk of bias (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>), with the remainder deemed to be at high risk (28 studies). </p> <section id="CD008738-sec-0086"> <h4 class="title">Allocation</h4> <p>All included studies reported that the allocation sequence was generated randomly, but only seven trials described the method used in sufficient detail. In these seven trials, adequate sequence generation methods were applied: i.e. computer‐generated codes (<a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>); random‐number table (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>), and shuffled cards (<a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>). </p> <p>Allocation concealment was described in four studies. Centralised randomisation was performed at a central trial office (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>), and an hospital pharmacy department (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>). </p> </section> <section id="CD008738-sec-0087"> <h4 class="title">Blinding</h4> <p>Seven trials were open (<a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>), and one was partially blinded (<a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). The <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a> trial report did not provide enough information about the blinding of participants, but the authors reported that the professional who administered the intervention was not blinded. In eighteen trials, although not explicitly stated, it appeared that neither participants, personnel nor outcome assessors were blinded (<a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). </p> <p>In ten trials it was possible that participants and personnel were blinded (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>). </p> <p>Seven trials reported the methodology used to assess outcomes with sufficient detail to establish that this had been done in a blinded manner, and this methodology was considered adequate (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). Four trials that blinded participants and personnel, did not appear to blind outcome assessment (<a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>). </p> </section> <section id="CD008738-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>Four trials reported post‐randomisation losses greater than 20% during the study (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>;<b> </b><a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>); eleven studies reported losses less than 20% during the study (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>); and two trials reported no losses (<a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>). For the remaining studies, the magnitude of such losses could not be determined. Fourteen trials reported the reasons for these losses (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). </p> <section id="CD008738-sec-0089"> <h5 class="title">Intention‐to‐treat (ITT) analysis</h5> <p>Twenty‐two trials (61%) used intention‐to‐treat analysis (ITT). ITT was not implemented in ten studies (<a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>), and it was unclear, or there was not enough information to determine whether ITT had been implemented, in the remaining four (<a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>). </p> </section> <section id="CD008738-sec-0090"> <h5 class="title">Incomplete outcome data</h5> <p>The overall assessment for incomplete outcome data was that the risk of bias was low for 13 studies (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="https://mail.google.com/mail/html/compose/static_files/de%20La%20Cal%202005" target="_blank">de La Cal 2005</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>), high in four studies  (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>;<b> </b><a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>), and unclear for the remaining studies. </p> </section> </section> <section id="CD008738-sec-0091"> <h4 class="title">Selective reporting</h4> <p>We carried out a search for the protocols of the included studies (searched 1995 to March 2012), but none was identified. Nonetheless, 27 (75%) of the included studies presented all the results that had been specified in the methods section of the article, and, therefore, we assumed there was no selective reporting. </p> </section> <section id="CD008738-sec-0092"> <h4 class="title">Other potential sources of bias</h4> <section id="CD008738-sec-0093"> <h5 class="title">Randomisation unit</h5> <p>Six studies included randomisation of more than one burn on the same participant: (<a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>, <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>, <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>, <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>, <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>, <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). Two trials generally randomised only a single burn for each participant (<a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>, <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>), but also included some participants with more than one burn wound, where wounds were randomised to different treatments (control and experimental). These trials randomised 43 and 52 participants, and analysed 50 and 56 burns, respectively. Four trials included only participants with at least two burn wounds that were randomised to different treatments (control and experimental) (<a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). </p> </section> <section id="CD008738-sec-0094"> <h5 class="title">Baseline imbalance</h5> <p>No study reported relevant baseline differences regarding factors that could influence results (for example, sociodemographic variables, size of the burn, aetiology, and post‐burn time). </p> </section> <section id="CD008738-sec-0095"> <h5 class="title">Early stopping</h5> <p>One study (<a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>), originally designed to include 90 patients, was stopped early due to the occurrence of poor results, and data were evaluated after 45 patients had completed the study. For this reason, the 'other potential sources of bias' domain for this study was judged to be at high risk of bias. </p> </section> </section> </section> <section id="CD008738-sec-0096"> <h3 class="title" id="CD008738-sec-0096">Effects of interventions</h3> <p>The 36 included trials evaluated different antibiotic interventions for prevention of infection in people with burn wounds. For each comparison between antibiotic prophylaxis and the corresponding control group, we present results for the primary and secondary outcomes of the review, if they had been evaluated in the study, and where information was available. </p> <p>The results are summarized in narrative form and, where possible and appropriate, through the corresponding meta‐analysis. Meta‐analysis, however, could not be performed for all comparisons, either because studies used different outcome measures, or because they did not provide all the information required. No studies were included that used a cluster randomized design (studies with group‐level allocation of interventions). </p> <p>It is inappropriate to analyse data for the time to an event, such as time to healing, with the methods used for continuous outcomes (e.g. using the mean time to the event), since pertinent times are known only in the subset of participants in which the event occurred (e.g. healing). The incorrect analysis of outcome data may introduce bias in the interpretation of results. All studies analysed the time to healing as a continuous quantitative variable, except <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>. Given that the estimate of effect carried out in this manner may not have been appropriate, we decided not to conduct a meta‐analysis for this outcome. </p> <p>The results of the studies were grouped according to the type of antibiotic prophylaxis evaluated: topical, systemic (general and perioperative), non‐absorbably, local and antibiotic prophylaxis with unspecified regimens. Outcomes were reported variably across the trials, therefore, where an outcome is absent from a comparison, this was not reported in any of the trials of that comparison. </p> <section id="CD008738-sec-0097"> <h4 class="title">1. Topical antibiotic prophylaxis</h4> <p>Twenty‐six trials (1329 participants) evaluated topical antibiotics compared with either an active or inactive control intervention. </p> <section id="CD008738-sec-0098"> <h5 class="title">Comparison 1: Neomycin, bacitracin, and polymyxin B compared with inactive control (no intervention or placebo) </h5> <p>Two trials (99 participants) evaluated a topical antibiotic compared with an inactive control (<a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>). <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> had three arms: Polybactrin spray (combination of neomycin, bacitracin and polymyxin B) (33 participants), Dermoplast spray (benzocaine 4.5%, benzethonium chloride1.1%, menthol 0.5%, methyl paraben 2% and 8‐hydroxyquinoline 0.83 %) (33 participants), and control (no spray) (33 participants). <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> also had three arms: neomycin plus bacitracin (bacitracin/polymyxin B) (18 participants), 0.5% silver nitrate (19 participants) and placebo (Ringer's lactate) (15 participants). </p> <section id="CD008738-sec-0099"> <h6 class="title">Outcome 1: Burn wound infection</h6> <p>Pooled data showed there was no significant difference in the number of participants with burn wound infection between Polybactrin or neomycin plus bacitracin and control group (OR = 0.75; 95% CI: 0.32 to 1.73), (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0004" title="">Analysis 1.1</a>)<i>.</i> The overall risk of bias for this outcome was high for both trials. Follow‐up was complete for <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>, but, overall, there was a high rate of post‐randomisation exclusions in <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>. The incidence of three invasive infections were measured. </p> </section> <section id="CD008738-sec-0100"> <h6 class="title">Outcome 2: Infections in the burned people</h6> <p><a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> (33 participants) reported that four participants developed sepsis in the neomycin plus bacitracin group compared with none in the control group however this difference was not statistically significant (RR = 7.58; 95% CI: 0.44 to 130.38) (<a href="./references#CD008738-fig-0005" title="">Analysis 1.2</a>); the overall risk of bias was high. No participant developed pneumonia. </p> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> (66 participants) reported that none of the participants developed sepsis; two participants in the Polybactrin group developed bacteraemia, compared with five in the control group, but this difference was not statistically significant (RR = 0.40; 95% CI: 0.08 to 1.92) (<a href="./references#CD008738-fig-0006" title="">Analysis 1.3</a>); there was a high risk of bias for this latter outcome. </p> </section> <section id="CD008738-sec-0101"> <h6 class="title">Outcome 3: Infection‐related mortality</h6> <p>In <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>, four participants in the neomycin plus bacitracin group died as a consequence of sepsis and multiple organ failure, compared with none in the Ringer’s lactate group, but this difference was not statistically significant (RR = 7.58; 95% CI: 0.44 to 130.38) (<a href="./references#CD008738-fig-0010" title="">Analysis 1.7</a>). Results for this trial are presented as an available data analysis, since there was a high rate of post‐randomisation exclusions in this study and only 52 of 90 randomised participants were included in the analysis. The overall risk of bias for this outcome was high. </p> </section> <section id="CD008738-sec-0102"> <h6 class="title">Outcome 5: Objective measures of wound healing</h6> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>: the mean time of healing of burn wounds was 22 days in the Polybactrin group, and 24 days in the control group (<a href="#CD008738-tbl-0002">Table 2</a>). According to the study authors, these differences were not significant (P value not reported). There was an overall high risk of bias for this outcome. </p> <div class="table" id="CD008738-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Time to complete wound healing</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study or Subgroup</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hazard Ratio</b> </p> <p><b>(HR)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Neomycin, bacitracin and polymyxin B vs control/placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Silver sulfadiazine vs polymyxin B/bacitracin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.0007</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Silver sulfadiazine vs dressings (skin substitute)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.517</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.0002</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.002</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Silver sulfadiazine vs any topical preparation of natural products (traditional medicine)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.0001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Topical antibiotic prophylaxis vs other treatments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Other topical antibiotics vs dressings (skin substitute)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Non‐absorbable antibiotic prophylaxis vs placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations</b> </p> <p>&lt; = less than<br/> vs = versus </p> </div> </div> <p>Only <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a> presented this outcome as a time‐to‐event outcome, not as continuous data, therefore, a pooled estimate was not produced. </p> </section> <section id="CD008738-sec-0103"> <h6 class="title">Outcome 6: Antibiotic resistance</h6> <p><a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> found no statistically significant difference between the frequency of participants with methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) in the neomycin plus bacitracin group (2/18) and the placebo group (3/15) (RR = 0.56; 95% CI: 0.11 to 2.90) (<a href="./references#CD008738-fig-0011" title="">Analysis 1.8</a>). The overall risk of bias for this outcome was high. </p> </section> <section id="CD008738-sec-0104"> <h6 class="title">Outcome 8: Length of hospital stay</h6> <p><a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> reported that the mean length of hospital stay (LOS) was 36.33 days in the neomycin plus bacitracin group and 40 days in the placebo group. There were no statistically significant differences between the groups (MD = ‐3.67 days; 95% CI: ‐9.46 to 2.12) (<a href="./references#CD008738-fig-0013" title="">Analysis 1.10</a>). The overall risk of bias for this outcome was high. </p> </section> </section> <section id="CD008738-sec-0105"> <h5 class="title">Comparison 2: Silver sulfadiazine compared with polymyxin B/bacitracin</h5> <p>One trial (15 participants, 30 burn wounds) compared silver sulfadiazine (SSD) cream with topical polymyxin B sulphate/bacitracin spray and collagenase ointment, with participants acting as their own control (there were two non‐contiguous wounds per participant of similar size and acuteness) (<a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). </p> <p><b>Outcome 4: Adverse events</b> </p> <p><a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a> found no adverse events in the group allocated to silver sulfadiazine (SSD), while there were three adverse events in the polymyxin B sulfate/bacitracin‐collagenase group (no statistically significant difference; OR = 0.20; 95% CI: 0.02 to 2.16) (<a href="./references#CD008738-fig-0009" title="">Analysis 1.6</a>). Denominator values suggested complete follow‐up, but the overall risk of bias for this outcome was high. </p> <p><b>Outcome 5: Objective measures of wound healing</b> </p> <p><a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a> presented data on mean healing time (complete epithelialization) with this comparison. Results reported that time to healing was significantly shorter with polymyxin B sulphate/bacitracin plus collagenase (10 days) than with SSD (15 days) (P value 0.007) (<a href="#CD008738-tbl-0002">Table 2</a>). This time‐to‐event outcome was presented as continuous data and, therefore, we have presented the data in narrative form only. The overall risk of bias for this outcome was high. </p> </section> <section id="CD008738-sec-0106"> <h5 class="title">Comparison 3: Silver sulfadiazine compared with dressings or skin substitute</h5> <p>Eleven trials (645 participants) compared 1% SSD cream with some kind of synthetic, or biosynthetic, dressing or skin substitute (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). Two studies compared SSD cream with silicone‐coated nylon (Mepitel) (<a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>). Six trials compared SSD cream with biosynthetic skin substitute dressing. The commercial brands studied were Biobrane (Smith &amp; Nephew) (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>), Transcyte (Smith &amp; Nephew) (<a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>), Xenoderm (Medical Biomaterial Products, Germany) (Hosseini 2009), and Kollagen sheet (<a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). Three trials compared SSD compared with a silver‐impregnated dressing. Products studied were Acticoat (Smith &amp; Nephew) (<a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>), AQUACEL (ConvaTec, a Bristol‐Myers Squibb company) (<a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>), and the ionic silver dressing combined with hydrogel (<a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>). </p> <section id="CD008738-sec-0107"> <h6 class="title">Outcome 1: Burn wound infection</h6> <p>Meta‐analysis of the 11 trials (645 participants) indicated a statistically significant increase in infection among patients receiving SSD compared with patients receiving dressing/skin substitute (OR = 1.87; 95% CI: 1.09 to 3.19, I<sup>2</sup> = 0% ) (<a href="./references#CD008738-fig-0004" title="">Analysis 1.1</a>). </p> <p>Interpretation of these results needs to take the overall risk of bias of the analysed trials into account. Only two trials had complete follow‐up, and an overall unclear risk of bias for this outcome (<a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>). The remaining nine trials had an overall high risk of bias for this outcome (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>), although in some trials there was almost complete follow‐up (<a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>).<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a> </p> </section> <section id="CD008738-sec-0108"> <h6 class="title">Outcome 2: Infections in the burned people</h6> <p><a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a> (20 participants) reported this outcome, and no participants developed bacteraemia. Denominator values suggested complete follow‐up, and the overall risk of bias for this outcome was high. </p> </section> <section id="CD008738-sec-0109"> <h6 class="title">Outcome 4: Adverse events</h6> <p>The results of four trials, with 302 participants, were pooled (<a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>); there was no statistically significant difference in adverse event rates between SSD and its comparators (dressings or skin substitute) (OR = 1.00; 95% CI: 0.47 to 2.14; I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0009" title="">Analysis 1.6</a>) . </p> <p><a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a> mentioned that three participants reported bleeding, and this outcome had an overall unclear risk of bias. <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a> reported that at least 45% of participants developed one or more adverse events in both trial arms, and had an overall high risk of bias for this outcome. <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a> and <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a> reported no adverse events in either group. </p> </section> <section id="CD008738-sec-0110"> <h6 class="title">Outcome 5: Objective measures of wound healing</h6> <p>Nine studies provided data on time to wound healing (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>), however, while all authors reported the mean time to healing in each group, they did not provided complete data for time‐to‐event analysis. Therefore, we could not pool the trial data to estimate the hazard ratio, and the lack of a standard deviation around the mean in several trials meant we could not produce a pooled estimate of mean difference either. The results of each trial are presented in <a href="#CD008738-tbl-0002">Table 2</a>. </p> <p>All trials showed an overall high risk of bias for this outcome except for <a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>, where the risk of bias for this outcome was unclear. </p> </section> <section id="CD008738-sec-0111"> <h6 class="title">Outcome 6: Antibiotic resistance</h6> <p><a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a> was the only trial that reported on antibiotic resistance. The results from this trial showed a lack of precision around the point estimate, so there were no statistically significant differences in the risk of development of MRSA between the SSD (3/25 participants) and the dressing impregnated with silver (2/25 participants) groups (RR = 1.50; 95% CI: 0.27 to 8.22) (<a href="./references#CD008738-fig-0011" title="">Analysis 1.8</a>). The overall risk of bias for this outcome was unclear. </p> </section> <section id="CD008738-sec-0112"> <h6 class="title">Outcome 7: All‐cause mortality</h6> <p>Two studies (132 participants) reported data on mortality, with only one death in one study (<a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>), and none in the other (<a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>). Meta‐analysis showed an important lack of precision in estimations and it was not possible to determine whether there were differences in mortality between SSD and the silver‐impregnated dressings  (RR = 0.35; 95% CI: 0.01 to 8.34) (<a href="./references#CD008738-fig-0012" title="">Analysis 1.9</a>). In <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a> there was an overall high risk of bias for this outcome. </p> </section> <section id="CD008738-sec-0113"> <h6 class="title">Outcome 8: Length of hospital stay</h6> <p>Four studies (196 participants) provided data on length of hospital stay (LOS) (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>; <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>). <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a> was not included in the meta‐analysis because no information was provided on the standard deviation around the mean. The meta‐analysis included the other three trials and showed a statistically significantly greater LOS among participants treated with SSD than for those given standard dressings (MD = 2.11 days; 95% CI: 1.93 to 2.28; I<sup>2</sup> = 36%) (<a href="./references#CD008738-fig-0013" title="">Analysis 1.10</a>). Two trials had an overall high risk of bias for this outcome (<a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>), and one had an overall unclear risk of bias (<a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a>). </p> </section> </section> <section id="CD008738-sec-0114"> <h5 class="title">Comparison 4: Silver sulfadiazine compared with any topical preparation of natural products (traditional medicine) </h5> <p>Four trials (333 participants) compared 1% SSD cream with any topical preparation of natural products (traditional medicine) (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>). The natural products tested were an oil‐based ointment (MEBO) with sesame oil, beta‐sisterol, berberine and small concentrations of other herbal ingredients (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>), <i>Aloe vera</i> cream (<a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>), a herbal cream with <i>Aloe vera</i> , <i>Geranium robertianum</i> , and <i>Lavandula stoechas</i> (<a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>), and unprocessed undiluted honey obtained from hives (<a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>). </p> <section id="CD008738-sec-0115"> <h6 class="title">Outcome 1: Burn wound infection</h6> <p>All trials (333 participants) provided data for this outcome (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>). These trials reported burn infection at different time points. None of these trials individually found a statistically significant difference in rates of burn wound infection between SSD and the natural product. Meta‐analysis of these results showed no overall statistically significant difference in the incidence of infection (OR = 1.05; 95% CI: 0.54 to 2.06; I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0004" title="">Analysis 1.1</a>). Overall risk of bias for this outcome was either high (<a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>; <a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a>), or unclear (<a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>). </p> </section> <section id="CD008738-sec-0116"> <h6 class="title">Outcome 2: Infections in burned people</h6> <p>Only <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a> (112 participants) reported on invasive infections: There was no statistically difference between groups in: the incidence of bacteraemia in the first (RR = 0.70; 95% CI: 0.16 to 2.98) (<a href="./references#CD008738-fig-0006" title="">Analysis 1.3</a>) or second (one participant in each group developed bacteraemia) week of follow‐up; the incidence of respiratory tract infection during the first (RR = 2.80; 95% CI: 0.12 to 67.21) (<a href="./references#CD008738-fig-0007" title="">Analysis 1.4</a>) or second (2/58 participants in the SSD group and 1/54 patients in the MEBO group developed pneumonia) week of follow‐up; or the incidence of UTI during the first (RR = 0.47; 95% CI: 0.04 to 4.99) (<a href="./references#CD008738-fig-0008" title="">Analysis 1.5</a>) or second (one participant in each group developed UTI) week of follow‐up. There was an overall high risk of bias for all invasive infection outcomes. </p> </section> <section id="CD008738-sec-0117"> <h6 class="title">Outcome 3: Infection‐related mortality</h6> <p><a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a> reported that one participant in the SSD group died due to infection. There was no statistically significant in mortality but given only one death this comparison lacks statistical power (RR = 2.80, 95% CI: 0.12 to 67.21). The overall risk of bias for this outcome was high. </p> </section> <section id="CD008738-sec-0118"> <h6 class="title">Outcome 5: Objective measures of wound healing</h6> <p><a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>, <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>, and <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a> reported on this outcome. In <a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>, the mean time needed for 75% epithelisation of the wound was 20 days in the SSD group and 17 days in the MEBO group (no statistically significant difference, hazard ratio [HR]: 0.67; 95%CI: 0.41 to 1.11; P value 0.11) (<a href="#CD008738-tbl-0002">Table 2</a>). In <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>, the mean time to wound healing was significantly longer in the SSD group than in the cream of Aloe vera group. In <a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a>, the mean time to healing was significantly longer in the cream made from herbs group than in the SSD group (<a href="#CD008738-tbl-0002">Table 2</a>). </p> <p>The overall risk of bias was unclear except for <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>, where it was high. </p> </section> <section id="CD008738-sec-0119"> <h6 class="title">Outcome 6: Antibiotic resistance</h6> <p><a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a> reported on the test results for detection of MRSA performed 14 days after treatment. The difference in MRSA incidence between the SSD and the silver‐coated dressing groups was not statistically significant (RR = 1.08; 95% CI: 0.66 to 1.76). (<a href="./references#CD008738-fig-0011" title="">Analysis 1.8</a>). The overall risk of bias was high. </p> </section> <section id="CD008738-sec-0120"> <h6 class="title">Outcome 7: All‐cause mortality</h6> <p><a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a> reported no significant differences between SSD and MEBO groups on the risk of mortality (RR = 1.86; 95% CI: 0.17 to 19.95) (<a href="./references#CD008738-fig-0012" title="">Analysis 1.9</a>). The overall risk of bias for this outcome was high. </p> </section> </section> <section id="CD008738-sec-0121"> <h5 class="title">Comparison 5: Other topical antibiotics compared with dressings or skin substitute</h5> <p>Three trials (85 participants) evaluated a non‐SSD topical antibiotic (bacitracin or mafenide acetate) compared with a synthetic or biosynthetic dressing or a skin substitute (<a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>). Two trials compared the bacitracin ointment with a biosynthetic skin substitute dressing, TransCyte (<a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a>; <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>). Silver 2007 evaluated mafenide acetate solution (Sulfamylon 5%) applied with a dressing (Exu‐Dry, Smith &amp; Nephew) compared with a silver dressing (Acticoat, Smith &amp; Nephew). </p> <section id="CD008738-sec-0122"> <h6 class="title">Outcome 1: Burn wound infection</h6> <p>None of the participants included in the three trials developed burn wound infection. We did not perform meta‐analysis with these studies because all of them presented no events in both arms. </p> </section> <section id="CD008738-sec-0123"> <h6 class="title">Outcome 4: Adverse events</h6> <p><a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a> (20 participants) reported that no participant presented with serious adverse events. </p> </section> <section id="CD008738-sec-0124"> <h6 class="title">Outcome 5: Objective measures of wound healing</h6> <p>In <a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a> the mean time to wound healing (defined as 90% or more re‐epithelization) was significantly longer in the bacitracin group than in the biosynthetic dressing group. In <a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>, the mean time to healing (cicatrisation; defined as 95% or more re‐epithelisation) was significantly longer in the bacitracin group than in the biosynthetic dressing group (<a href="#CD008738-tbl-0002">Table 2</a>). </p> </section> </section> <section id="CD008738-sec-0125"> <h5 class="title">Comparison 6: Topical antibiotic prophylaxis compared with other treatments</h5> <p>Seven trials (353 participants) evaluated a topical antibiotic compared with other treatments of topical administration (<a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>). <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a> evaluated gentamicin cream 1% applied by iontophoresis compared with routine care (cleaning and change of dressings). <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> had three treatment arms: neomycin spray, Polybactrin, Dermoplast spray, and control (no spray). <a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a> compared SSD cream (Silvadene) with silver ions hydrogel (SilvaSorb Gel). <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a> compared SSD cream (Flammazine, Solvay Arzneimittel GmbH, Hannover, Deutschland) with a hydrosome gel (Repithel, Mundipharma GmbH, Limburg/Lahn, Deutschland). <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> had three treatment arms: neomycin, bacitracin plus (bacitracin/polymyxin B) , silver nitrate 0.5% and placebo (Ringer's lactate). <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a> compared rifamycin and amniotic membranes with amniotic membranes alone. Lastly, <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a> compared either SSD or mafenide acetate with amniotic membranes. </p> <section id="CD008738-sec-0126"> <h6 class="title">Outcome 1: Burn wound infection</h6> <p>Pooling the seven trials indicated no statistically significant difference in rates of burn wound infection between the antibiotic prophylaxis and control groups (OR = 1.51; 95% CI: 0.94 to 2.42, with no statistical heterogeneity (I² = 0%)) (<a href="./references#CD008738-fig-0004" title="">Analysis 1.1</a>). The overall risk of bias for this outcome was high for all the pooled trials. </p> </section> <section id="CD008738-sec-0127"> <h6 class="title">Outcome 2: Infections in burned people</h6> <p>Three trials (227 participants) provided data on purulence with septicaemia (<a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>), and sepsis (<a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>). Meta‐analysis of these three trials showed a significantly greater incidence of sepsis among participants receiving antibiotic prophylaxis than for the group given other treatments (RR = 4.31; 95% CI: 1.61 to 11.49), with no statistical heterogeneity (I² = 0%) (<a href="./references#CD008738-fig-0005" title="">Analysis 1.2</a>). The overall risk of bias for this outcome was high for the three trials (<a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>). </p> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> (66 participants) did not show a statistically significant difference in the incidence of bacteraemia between the Polybactrin group and the Dermoplast group (RR = 0.67; 95% CI: 0.12 to 3.73) (<a href="./references#CD008738-fig-0006" title="">Analysis 1.3</a>). Denominator values suggested complete follow‐up, but the overall risk of bias was high. </p> <p>In <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> (37 participants), one participant developed pulmonary sepsis in the silver nitrate group, but the difference was not statistically significant (RR = 0.35; 95% CI: 0.02 to 8.09) (<a href="./references#CD008738-fig-0007" title="">Analysis 1.4</a>). The overall risk of bias was high. </p> </section> <section id="CD008738-sec-0128"> <h6 class="title">Outcome 3: Infection‐related mortality</h6> <p>In <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>, four out of 18 participants in the neomycin plus bacitracin group and one out of 19 participants in the silver nitrate group died due to sepsis and multiple organ failure. The estimations of the effect of interventions on these outcomes showed an important lack of precision that does not allow valid conclusions to be drawn (RR = 4.22; 95% CI: 0.52 to 34.28) (<a href="./references#CD008738-fig-0010" title="">Analysis 1.7</a>). Due to the high rate of post‐randomisation exclusions in this study (only 52 of 90 randomised participants were included in the analysis), the overall risk of bias was high. </p> </section> <section id="CD008738-sec-0129"> <h6 class="title">Outcome 4: Adverse events</h6> <p><a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a> (24 participants) was the only trial that reported on adverse events. The results from this trial stated that no participants developed adverse events during the study. </p> <p><b>Outcome 5: Objective measures of wound healing</b> </p> <p>In <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>, there was no statistical difference in mean healing time of wounds between the Polybactrin group and the Dermoplast group. In <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>, burns were reviewed and evaluated by two independent investigators and time to complete healing was found to be longer in the SSD group than in the Repithel cream group; this difference was statistically significant (<a href="#CD008738-tbl-0002">Table 2</a>). The time‐to‐event outcome was presented as continuous data, so we have presented the data in narrative form only. </p> </section> <section id="CD008738-sec-0130"> <h6 class="title">Outcome 6: Antibiotic resistance</h6> <p>In <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> there were no statistically significant differences regarding the frequency of participants with MRSA between the two groups (neomycin, plus bacitracin group 2/18; and the silver nitrate group 0/19) (RR = 5.26; 95% CI: 0.27 to 102.66) (<a href="./references#CD008738-fig-0011" title="">Analysis 1.8</a>). The overall risk of bias for this outcome was high. </p> </section> <section id="CD008738-sec-0131"> <h6 class="title">Outcome 7: All‐cause mortality</h6> <p>Two trials (181 participants) provided data on all‐cause mortality for neomycin plus bacitracin compared with silver nitrate (<a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>), and SSD or mafenide acetate compared with amniotic membrane (<a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>). The meta‐analysis of these two trials showed a statistically significantly higher incidence of mortality among participants treated with antibiotic prophylaxis than for the group that received other treatments (RR = 5.95; 95% CI: 1.10 to 32.33), with no statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0012" title="">Analysis 1.9</a>). The overall risk of bias for this outcome was high for both trials. </p> <p>Additionally, the report of <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> indicated that four more participants died during the study (two from myocardial infarction and two from pulmonary emboli), but the group(s) to which these participants belonged was not specified<i>.</i> Because of this, it was not possible to include this data in the main analysis. A sensitivity analysis was carried out with this data (see Dealing with missing data, Sensitivity analysis) which did not find differences with respect to the main analysis. </p> </section> <section id="CD008738-sec-0132"> <h6 class="title">Outcome 8: Length of hospital stay</h6> <p>Four trials (216 participants) provided data on LOS for this comparison (<a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>). </p> <p>In <a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>, the mean time for LOS was shorter in the gentamicin cream group than in the routine care group. This difference was statistically significant (MD = ‐12.00 days; 95% CI: ‐17.52 to ‐6.48). <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> did not find a statistically significant difference in length of stay between neomycin/bacitracin and silver nitrate (MD = 3.03; 95% CI: ‐2.01 to 8.07). In <a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>, the mean LOS was significantly shorter in the rifamycin and amniotic membranes group than in the group with amniotic membranes alone (MD = ‐4.41 days; 95% CI: ‐8.17 to ‐0.65). <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a> reported that the mean LOS was significantly longer in the SSD arm compared with amniotic membranes (MD = 9.77; 95% CI: 7.29 to 12.25) (<a href="./references#CD008738-fig-0013" title="">Analysis 1.10</a>). </p> <p>The meta‐analysis of these four trials showed a high statistical heterogeneity (I² = 96%) (<a href="./references#CD008738-fig-0013" title="">Analysis 1.10</a>); therefore, its results are not presented. The risk of bias was high for the four trials. </p> </section> </section> </section> <section id="CD008738-sec-0133"> <h4 class="title">2. Systemic antibiotic prophylaxis (general)</h4> <p>Three trials (119 participants) evaluated systemic antibiotics administered at admission or during routine treatment (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>). All three studies compared an antibiotic administered orally, or intravenously, with no treatment or placebo. <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a> evaluated penicillin (penicillin V (250 mg) orally every six hours or sodium penicillin 1.2 million units intravenously every 12 hours) compared with placebo. Most people received the medication or placebo orally for five days. <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a> compared trimethoprim‐sulfamethoxazole (TMP‐SMX) 1.0 g (400 mg SMX/TMP 80 mg) with placebo (lactose 1.0 g), both administered orally or by nasogastric tube three times a day. Other antibiotics such as ampicillin, cephazolin, cephamandole, cefmetazole, and flomoxef were administered in combination with TMP‐SMX or placebo when the attending physician deemed it necessary. <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a> evaluated polymyxin B compared with an inactive control (received no antibiotic prophylaxis). The antibiotic regimen was as follows: 5000 units/kg intravenously on the first day of the study, subsequently, doses were reduced by 500 units/kg per day until 1500 units was reached on the last day. </p> <section id="CD008738-sec-0134"> <h5 class="title">Outcome 1: Burn wound infection</h5> <p>Neither of the two trials comparing the effects of systemic antibiotics on burn wound infection identified a statistically significant difference in rates of burn infection. In <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a> 11 out of 25 people in the penicillin V group developed a burn wound infection compared with 7 out of 26 in the placebo group (RR = 1.63; 95% CI: 0.75 to 3.54) (<a href="./references#CD008738-fig-0014" title="">Analysis 2.1</a>). In <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>one person out of 15 in the polymixin B group developed a burn wound infection compared with five out of 13 in the no treatment group (RR = 0.17; 95% CI: 0.02 to 1.30) (<a href="./references#CD008738-fig-0014" title="">Analysis 2.1</a>). </p> <p>Meta analysis of these studies was inappropriate due to the high statistical heterogeneity (I² = 78%) (<a href="./references#CD008738-fig-0014" title="">Analysis 2.1</a>). Overall risk of bias for this outcome was either high (<a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>), or unclear (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>). </p> </section> <section id="CD008738-sec-0135"> <h5 class="title">Outcome 2: Infections in burned people</h5> <p>Two trials (59 participants) assessed incidence of sepsis with penicillin (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>) and polymyxin B (<a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>). Pooling the two trials (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>) did not indicate a statistically significant difference in the number of participants with sepsis between the antibiotic prophylaxis group and its comparators (RR = 0.43; 95% CI: 0.12 to 1.61 (P value 0.21)), with no statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0015" title="">Analysis 2.2</a>) however statistical power is low with only 10 events. Overall risk of bias for this outcome was either high (<a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>), or unclear (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>). </p> <p><a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a> (51 participants) reported data for beta‐haemolytic streptococcal bacteraemia: one participant developed bacteraemia in the penicillin group, but there were no statistically significant differences (RR = 3.12; 95% CI: 0.13 to 73.06) (<a href="./references#CD008738-fig-0016" title="">Analysis 2.3</a>).   </p> <p>In <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a> (40 participants), a significantly lower number of participants developed pneumonia in the trimethoprim‐sulfamethoxazole (TMP‐SMX) group than in the placebo group (RR = 0.18; 95% CI: 0.05 to 0.72) (<a href="./references#CD008738-fig-0017" title="">Analysis 2.4</a>). </p> <p>In <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>, one participant developed a UTI in the placebo group, but there were no statistically significant differences between the groups (RR = 0.35; 95% CI: 0.01 to 8.12) (<a href="./references#CD008738-fig-0018" title="">Analysis 2.5</a>). The overall risk of bias for all the invasive infection outcomes was unclear. </p> </section> <section id="CD008738-sec-0136"> <h5 class="title">Outcome 3: Infection‐related mortality</h5> <p>In <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>, one participant in the penicillin group died due to infection compared with three participants in the placebo group. In <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>, two participants in the control group died during the study as a consequence of sepsis. Pooling the two trials demonstrated a no significant difference regarding infection‐related mortality between comparison groups (RR = 0.27; 95% CI: 0.05 to 1.58), with no statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0019" title="">Analysis 2.6</a>). Overall risk of bias for this outcome was either high (<a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>), or unclear (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>). </p> </section> <section id="CD008738-sec-0137"> <h5 class="title">Outcome 4: Adverse events</h5> <p>In <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>, data on adverse events were not reported. <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a> and <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a> reported that none of the participants developed adverse events and, consequently, there were no dropouts attributable to adverse effects. There was an overall high risk of bias. </p> </section> <section id="CD008738-sec-0138"> <h5 class="title">Outcome 6: Antibiotic resistance</h5> <p><a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a> reported that there was a statistically significantly lower frequency of patients with MRSA in those treated with TMP‐SMX than in those treated with placebo (RR = 0.13; 95% CI: 0.02 to 0.96) (<a href="./references#CD008738-fig-0020" title="">Analysis 2.7</a>). There was an unclear overall risk of bias. </p> </section> <section id="CD008738-sec-0139"> <h5 class="title">Outcome 7: All‐cause mortality</h5> <p>Three trials (109 participants) presented data on all‐cause mortality, comparing penicillin (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>), TMP‐SMX (<a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>) or polymyxin B (<a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>) each with placebo or an inactive control. On pooling the results of these three trials (I= 0%) there was no statistically significant difference (RR = 0.41; 95% CI: 0.17 to 1.02) (<a href="./references#CD008738-fig-0021" title="">Analysis 2.8</a>). Overall risk of bias for this outcome was either high (<a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>), or unclear (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>). </p> </section> <section id="CD008738-sec-0140"> <h5 class="title">Outcome 8: Length of hospital stay</h5> <p>No significant difference was observed in LOS in <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a> between the penicillin and placebo groups (MD = 0.80 days; 95% CI: ‐1.47 to 3.07) (<a href="./references#CD008738-fig-0022" title="">Analysis 2.9</a>). There was an overall high risk of bias. </p> </section> </section> <section id="CD008738-sec-0141"> <h4 class="title">3. Systemic antibiotic prophylaxis (perioperative)</h4> <p>Four trials (390 participants) compared perioperative systemic antibiotics with an inactive control (no intervention or placebo) or another antibiotic (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). </p> <section id="CD008738-sec-0142"> <h5 class="title">Comparison 1: Antibiotic prophylaxis compared with no intervention or placebo (inactive control) </h5> <p>Three trials compared a systemic antibiotic with no treatment, or placebo, to prevent burn wound infection (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). <a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a> compared cephalothin 15 mg/kg intravenously with placebo (equal volume). Three doses were administered throughout the perioperative process. In <a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>, a systemic antibiotic administered for debridement and skin graft (perioperative) was compared with a control group without antibiotic prophylaxis. Selection of the antibiotic was based on the antibiotic sensitivity of the dominant organism, and on the cultures of the most recent wound. Participants who received therapeutic antibiotics did not receive further antibiotic prophylaxis. All antibiotics were administered intravenously. <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a> had four arms: where burns were less than 35% TBSA, cephazolin versus placebo and, where burns were more than 35% TBSA, cephazolin versus specific antibiotics. Cephazolin was administered at a dose of 25 mg/kg every six hours intravenously for 24 hours; the consultant for infectious diseases selected antibiotics specifically on the basis of the results of the most recent cultures. </p> <section id="CD008738-sec-0143"> <h6 class="title">Outcome 1 Burn wound infection</h6> <p>In <a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a> (249 participants), there was no statistically significant difference in the incidence of burn wound infection between the cephalothin and placebo groups (RR = 0.14; 95% CI: 0.02 to 1.10). There was an unclear overall risk of bias for this outcome. In <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a> (20 participants), there was no statistically significant difference in the incidence of burn wound infection between the cephazolin group and the placebo group (RR = 2.00; 95% CI: 0.21 to 18.69). </p> <p>Meta‐analysis for this outcome was inappropriate due to high heterogeneity (I² = 67%) (<a href="./references#CD008738-fig-0023" title="">Analysis 3.1</a>).There was an overall high risk of bias for this outcome. </p> </section> <section id="CD008738-sec-0144"> <h6 class="title">Outcome 2: Infections in burned people</h6> <p>Two trials (89 participants) reported the rates of bacteraemia (<a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). There was no statistically significant difference in bacteraemia between treatment groups (RR = 1.32; 95% CI: 0.31 to 5.60), with no statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0024" title="">Analysis 3.2</a>). There was an overall high risk of bias for this outcome for both trials. </p> </section> <section id="CD008738-sec-0145"> <h6 class="title">Outcome 4: Adverse events</h6> <p><a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a> one participant in each group presented scattered areas of cutaneous erythema (RR = 0.96; 95% CI: 0.06 to 15.19) (<a href="./references#CD008738-fig-0027" title="">Analysis 3.5</a>). There was an unclear risk of bias. </p> </section> <section id="CD008738-sec-0146"> <h6 class="title">Outcome 7: All‐cause mortality</h6> <p>In <a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a> the difference between groups for all‐cause mortality was not statistically significant (RR = 1.62; 95% CI: 0.42 to 6.25) (<a href="./references#CD008738-fig-0028" title="">Analysis 3.6</a>). There was an overall high risk of bias for this outcome. </p> </section> <section id="CD008738-sec-0147"> <h6 class="title">Outcome 8: Length of hospital stay</h6> <p>In <a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>, the mean LOS was 12.38 days in the cephalothin group and 13.66 days in the placebo group; this difference was statistically significant (MD = ‐1.28; 95% CI: ‐2.64 to 0.08; P value less than 0.02) (<a href="./references#CD008738-fig-0029" title="">Analysis 3.7</a>). There was an unclear risk of bias . </p> </section> </section> <section id="CD008738-sec-0148"> <h5 class="title">Comparison 2: Cephazolin compared with another antibiotic</h5> <p>Two trials (51 participants) compared cephazolin with another antibiotic (<a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a> compared  cephazolin 1g intravenously (three doses, the first one hour before surgery and two more doses six and 12 hours after the first dose) with ceforanide 1g intravenously applied one hour before surgery. <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a> had four treatment arms; cephazolin versus placebo (where burns were less than 35% TBSA), and cephazolin versus specific antibiotics (burns more than 35% TBSA). Cephazolin was administered intravenously at a dose of 25 mg/kg every six hours for 24 hours. </p> <section id="CD008738-sec-0149"> <h6 class="title">Outcome 1: Burn wound infection</h6> <p>Two trials provided data for this outcome, either in comparison with ceforanide (<a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>), or with a specific, targeted antibiotic (<a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). Pooling of data failed to demonstrate significant differences in burn wound infection between comparison groups (RR = 0.99; 95% CI: 0.49 to 2.01, with no statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0023" title="">Analysis 3.1</a>). The overall risk of bias for this outcome was high for both trials. </p> </section> <section id="CD008738-sec-0150"> <h6 class="title">Outcome 2: Infections in burned people</h6> <p><a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a> (four participants) showed no statistically significant differences in bacteraemia between cephazolin and the specific antibiotic group (RR = 0.83; 95% CI: 0.28 to 2.51) (<a href="./references#CD008738-fig-0024" title="">Analysis 3.2</a>). </p> <p><a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a> (47 participants) reported that one participant developed pneumonia during the study in the ceforanide group, but the difference was not statistically significant (RR = 0.32; 95% CI: 0.01 to 7.48) (<a href="./references#CD008738-fig-0025" title="">Analysis 3.3</a>). </p> <p><a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a> reported that one participant developed urinary tract infection during the study in the cephazolin group, but this difference was not statistically significant (RR = 2.88; 95% CI: 0.12 to 67.29) (<a href="./references#CD008738-fig-0026" title="">Analysis 3.4</a>). There was an overall high risk of bias for all invasive infection outcomes. </p> </section> <section id="CD008738-sec-0151"> <h6 class="title">Outcome 4: Adverse events</h6> <p><a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a> reported that no participant in the cephazolin or ceforanide groups presented with adverse events. </p> </section> </section> </section> <section id="CD008738-sec-0152"> <h4 class="title">4. Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract (SDD)) </h4> <p>Two trials (140 participants) evaluated non absorbable antibiotic prophylaxis using selective decontamination of the digestive tract (SDD) compared with placebo (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>). <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> evaluated polymyxin E suspension (100 mg), tobramycin (100 mg), and amphotericin B (500 mg) by nasogastric tube four times a day compared with physiologic isotonic solution (Ringer's lactate). Additionally, systemic antibiotics (vancomycin, amikacin, and piperacillin) were administered preoperatively in both study arms in order to prevent sepsis and bacteraemia. <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a> evaluated (1) polymyxin E (100 mg), tobramycin (100 mg) and amphotericin B (500 mg) administered orally four times a day; (2) cefotaxime 1 g iv 8‐hourly for 4 days; (3) non absorbable polymyxin E, tobramycin and amphotericin B 0.5 g of a 2% paste, topical application in the oropharynx 4 times/day, compared to (1) placebo solution administered orally; (2) placebo solution, isotonic 0.9% saline iv; (3) placebo paste, topical application in the oropharynx. The placebo solution was indistinguishable from the test drug with respect to colour, smell, and consistency. Other systemic antibiotics, such as vancomycin, ceftazidime and aminoglycosides, were administered empirically in both study arms when people developed clinical signs of infection; antibiotic treatment in these people was adjusted according to microbiological results. </p> <section id="CD008738-sec-0153"> <h5 class="title">Comparison 1: non‐absorbable antibiotic prophylaxis versus placebo</h5> <p>One trial with 23 participants compared non‐absorbable antibiotic prophylaxis, through selective decontamination of the digestive tract, against placebo (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>). </p> <section id="CD008738-sec-0154"> <h6 class="title">Outcome 2: Infections in burned people</h6> <p>There was no statistically significant difference in sepsis between the non‐absorbable antibiotic group and the placebo group for <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> (23 participants) (RR = 2.18; 95% CI: 0.49 to 9.65) (<a href="./references#CD008738-fig-0031" title="">Analysis 4.2</a>). </p> <p><a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> (23 participants) only one participant developed pneumonia in the non absorbable antibiotic group , the difference was not statistically significant (RR= 3.25; 95% CI: 0.15 to 72.36) (<a href="./references#CD008738-fig-0033" title="">Analysis 4.4</a>) The overall risk of bias was unclear for both outcomes. </p> </section> <section id="CD008738-sec-0155"> <h6 class="title">Outcome 4: Adverse events</h6> <p>In <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> (23 participants), significantly more participants in the non‐absorbable antibiotics group developed adverse events (diarrhoea or gastrointestinal bleeding) than in the placebo group (RR = 3.64; 95% CI: 1.34 to 9.86) (<a href="./references#CD008738-fig-0035" title="">Analysis 4.6</a>). The overall risk of bias was unclear.  </p> </section> <section id="CD008738-sec-0156"> <h6 class="title">Outcome 5: Objective measures of wound healing</h6> <p>In <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> there was no statistically significant difference in mean time to wound healing 40 ±8 days in the antibiotic group compared with 33±4 days in the placebo group (<a href="#CD008738-tbl-0002">Table 2</a>). There was an overall unclear risk of bias. </p> </section> <section id="CD008738-sec-0157"> <h6 class="title">Outcome 7: All‐cause mortality</h6> <p><a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> reported that two out of 11 participants in the non‐absorbable antibiotic group died from respiratory distress and one out of 12 participants in the placebo group died of a systemic fungal infection. There was no statistically significant difference in mortality between the groups (RR = 2.18; 95% CI: 0.23 to 20.84) (<a href="./references#CD008738-fig-0037" title="">Analysis 4.8</a>). The overall risk of bias for this outcome was unclear. </p> </section> <section id="CD008738-sec-0158"> <h6 class="title">Outcome 8: Length of hospital stay</h6> <p>In <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>, the mean LOS was significantly longer in the non‐absorbable antibiotic group (42 days) compared with the placebo group (35 days) (MD = 7.00 days; 95% CI: 3.28 to 10.72) (<a href="./references#CD008738-fig-0038" title="">Analysis 4.9</a>), and there was an overall low risk of bias for this outcome. The overall risk of bias for this outcome was unclear. </p> </section> </section> <section id="CD008738-sec-0159"> <h5 class="title">Comparison 2: non‐absorbable antibiotic prophylaxis and cefotaxime versus placebo.</h5> <p>One trial with 117 participants evaluated non‐absorbable antibiotic prophylaxis and cefotaxime, against placebo, however data are presented for 107 participants as there 10 post randomisation losses (<a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>). </p> <section id="CD008738-sec-0160"> <h6 class="title">Outcome 1: Burn wound infection</h6> <p>In <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a> (107 participants), there was no statistically significant difference between the number of participants with burn wound infection in the non‐absorbable antibiotics and cefotaxime group (10/53) compared with the placebo group (11/54) (RR = 0.93; 95% CI: 0.43 to 2.00) (<a href="./references#CD008738-fig-0030" title="">Analysis 4.1</a>). </p> </section> <section id="CD008738-sec-0161"> <h6 class="title">Outcome 2: Infections in burned people</h6> <p>There was no statistically significant difference in occurrence of bacteraemia between the non‐absorbable antibiotic and cefotaxime group and the placebo group for <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a> (107 participants) (RR = 1.14; 95% CI: 0.67 to 1.94) (<a href="./references#CD008738-fig-0032" title="">Analysis 4.3</a>). </p> <p>In <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a> 18/53 participants in the non absorbable antibiotic and cefotaxime group developed pneumonia during the study, compared with 26/54 participants in the placebo group, the difference was not statistically significant (RR= 0.71; 95% CI: 0.44 a 1.12) (<a href="./references#CD008738-fig-0033" title="">Analysis 4.4</a>). </p> <p>There were no statistically significant differences in urinary tract infection between groups for <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>  (RR = 0.44; 95% CI: 0.18 to 1.05) (<a href="./references#CD008738-fig-0034" title="">Analysis 4.5</a>). The overall risk of bias was unclear for all four infection‐related outcomes.    </p> </section> <section id="CD008738-sec-0162"> <h6 class="title">Outcome 6: Antibiotic resistance</h6> <p>In <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a> the results of colonization by organisms resistant to antibiotics were reported as endogenous secondary infections, which was defined as the colonization caused by micro‐organisms that were not present at admission, but that were acquired during treatment in the intensive care unit. </p> <p>According to <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>, the number of participants who developed an MRSA infection was significantly higher in the non‐absorbable antibiotics and cefotaxime group (24/53) than in the placebo group (11/54). This difference was statistically significant (RR = 2.22; 95% CI: 1.21 to 4.07) (<a href="./references#CD008738-fig-0036" title="">Analysis 4.7</a>). The overall risk of bias was unclear. </p> </section> <section id="CD008738-sec-0163"> <h6 class="title">Outcome 7: All‐cause mortality</h6> <p>In <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>, significantly fewer participants in the non‐absorbable antibiotics and cefotaxime group (5/53) died during the study than in the placebo group (15/54) (RR = 0.34; 95% CI: 0.13 to 0.87) (<a href="./references#CD008738-fig-0037" title="">Analysis 4.8</a>). The overall risk of bias for this outcome was unclear in both trials. </p> </section> <section id="CD008738-sec-0164"> <h6 class="title">Outcome 8: Length of hospital stay</h6> <p>In <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>, the mean LOS was 50.6 days in the non‐absorbable antibiotics and cefotaxime group and 52.3 days in the placebo group; this difference was not statistically significant (MD = ‐1.70 days; 95% CI: ‐15.82 to 12.42) (<a href="./references#CD008738-fig-0038" title="">Analysis 4.9</a>). The overall risk of bias for this outcome was unclear. </p> </section> </section> </section> <section id="CD008738-sec-0165"> <h4 class="title">5. Local antibiotic prophylaxis (airway)</h4> <p>Only one trial (30 participants) evaluated local antibiotics (gentamicin 80 mg in 2 ml of diluent) administered by airway compared with placebo (2 ml of saline solution) (<a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>). burns of all participants included in the study were treated with SSD cream (Silvadene) or mafenide acetate (Sulfamylon). </p> <section id="CD008738-sec-0166"> <h5 class="title">Outcome 2: Infections in burned people</h5> <p>There was no statistically significant difference in incidence of sepsis between the gentamicin and placebo group (RR = 1.04; 95% CI: 0.67 to 1.60) (<a href="./references#CD008738-fig-0039" title="">Analysis 5.1</a>). There was an overall high risk of bias. </p> </section> <section id="CD008738-sec-0167"> <h5 class="title">Outcome 7: All‐cause mortality</h5> <p>There was no statistically significant difference between the antibiotic and placebo groups for all‐cause mortality (RR = 0.75; 95% CI: 0.39 to 1.44) (<a href="./references#CD008738-fig-0040" title="">Analysis 5.2</a>). The overall risk of bias for this outcome was high. A significant number of participants who died in the placebo group had more than 60% of their total body surface area burned. </p> </section> </section> <section id="CD008738-sec-0168"> <h4 class="title">6. Antibiotic prophylaxis compared with <i>inactive control (no intervention or placebo)</i> </h4> <p>We now present a summary of the results of studies comparing any antibiotic with an inactive control (i.e. no intervention or placebo) (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>) (<a href="./references#CD008738-fig-0041" title="">Analysis 6.1</a> to <a href="./references#CD008738-fig-0050" title="">Analysis 6.10</a>). In this section, we just describe the results concerning the primary outcome variables of the review. </p> <section id="CD008738-sec-0169"> <h5 class="title">Outcome 1: Burn wound infection</h5> <p>Pooling seven trials (554 participants) revealed no statistically significant difference between treatments in the number of participants with burn wound infection (RR = 0.84; 95% CI: 0.51 to 1.39) (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>), with moderate statistical heterogeneity (I<sup>2</sup> = 38%) (<a href="./references#CD008738-fig-0041" title="">Analysis 6.1</a>). </p> </section> <section id="CD008738-sec-0170"> <h5 class="title">Outcome 2: Infections in burned people</h5> <p>Meta‐analysis of six trials (231 participants) showed no statistically significant difference between treatments in the number of participants who developed sepsis (RR = 1.06; 95% CI: 0.54 to 2.10) (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>), without relevant statistical heterogeneity (I<sup>2</sup> = 25%) (<a href="./references#CD008738-fig-0042" title="">Analysis 6.2</a>). </p> <p>Pooling of five trials (313 participants) (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>), showed no statistically significant difference between treatments for the number of participants who developed bacteraemia (RR = 1.08; 95% CI: 0.67 to 1.72), without statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0043" title="">Analysis 6.3</a>). </p> <p>Pooling of four trials (203 participants) suggested that the number of participants with pneumonia was lower in the antibiotic prophylaxis group (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>), however, given that the meta‐analysis had substantial heterogeneity (I² = 56%), its results are not presented (<a href="./references#CD008738-fig-0044" title="">Analysis 6.4</a>). </p> <p>Pooling of two trials (158 participants) revealed no statistically significant difference between treatments for the number of participants who developed UTI (RR = 0.43; 95% CI: 0.18 to 1.00) (<a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>), without statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0045" title="">Analysis 6.5</a>). </p> <p><b>Outcome 3: Infection‐related mortality</b> </p> <p>Pooling of two trials (79 participants) revealed no statistically significant differences between treatments for the number of participants who died of infection (RR = 0.27; 95% CI: 0.05 to 1.58) (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>), with no statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0046" title="">Analysis 6.6</a>). </p> </section> <section id="CD008738-sec-0171"> <h5 class="title">Outcome 4: Adverse events</h5> <p>Meta‐analysis of four trials (340 participants) showed that the number of participants who developed at least one adverse event was statistically higher in the antibiotic groups than in the control groups (RR = 3.12; 95% CI: 1.22 to 7.97) (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>), with no statistical heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0047" title="">Analysis 6.7</a>). </p> <p><b>Outcome 6: Antibiotic resistance</b> </p> <p>Pooling three trials (180 participants) showed no statistically significant difference between treatment groups for the number of participants who developed MRSA infection (<a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>), however, given that the meta‐analysis had high heterogeneity (I² = 79%), its results are not presented (<a href="./references#CD008738-fig-0048" title="">Analysis 6.8</a>). </p> </section> <section id="CD008738-sec-0172"> <h5 class="title">Outcome 7: All‐cause mortality</h5> <p>Pooling seven trials (348 participants) showed that a statistically significantly greater number of people died in the control group (RR = 0.62; 95% CI: 0.39 to 0.99) (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>), with low statistical heterogeneity (I<sup>2</sup> = 9%) (<a href="./references#CD008738-fig-0049" title="">Analysis 6.9</a>). </p> </section> <section id="CD008738-sec-0173"> <h5 class="title">Outcome 8: Length of hospital stay</h5> <p>Pooling five trials (463 participants) showed that there was no statistically significant difference between treatment groups for LOS (<a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>; <a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>; <a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>). However, given that the meta‐analysis had high heterogeneity (I² = 79%), its results are not presented (<a href="./references#CD008738-fig-0050" title="">Analysis 6.10</a>). </p> </section> </section> <section id="CD008738-sec-0174"> <h4 class="title">Subgroup analysis</h4> <p>We did not perform subgroup analyses considering the factors specified in the protocol (participants’ age and severity of the burn) due to a lack of data in the included studies; even though 15 of the 36 included studies included children and adults, none presented the results separately according to age group. </p> </section> <section id="CD008738-sec-0175"> <h4 class="title"><i>Sensitivity analysis</i> </h4> <section id="CD008738-sec-0176"> <h5 class="title">Analysis with 'cluster designs':</h5> <p>No cluster RCTs were identified.</p> </section> <section id="CD008738-sec-0177"> <h5 class="title">Risk of bias</h5> <p>Only one study was classified as ‘low risk of bias’ (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>), therefore, it was not possible to conduct the corresponding sensitivity analysis. </p> </section> <section id="CD008738-sec-0178"> <h5 class="title">Levels of missing data</h5> <p>Most of the included trials had low levels of missing data (less than 20%); one trial had 21% of data missing (<a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>), and three had more than 40% (<a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>). We performed a sensitivity analysis to explore the impact of the levels of missing data on the overall treatment effect for the main variable of burn wound infection. </p> <p>When comparing analyses of silver sulfadiazine versus dressings or skin substitutes, there was no significant difference between the analysis that included all studies (RR = 1.74; 95% CI: 1.08 to 2.79; I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0004" title="">Analysis 1.1</a>), and the analysis that included only studies with less than 20% of data missing (RR= 1.64; 95% CI: 1.02 to 2.65; I<sup>2</sup> = 0%). </p> <p>In the comparison of antibiotic prophylaxis versus other treatments, no significant difference was found when the analysis that included all studies (RR = 1.39; 95% CI: 1.11 to 1.75; I<sup>2</sup> = 0%) (<a href="./references#CD008738-fig-0004" title="">Analysis 1.1</a>) was compared with the analysis that included only studies with less than 20% of data missing (RR = 1.37; 95% CI: 1.07 to 1.74; I<sup>2</sup> = 0%), however, it was not possible to compare the results to the remaining comparisons because it was not possible to estimate the effect from studies with less than 20% of data missing. </p> </section> <section id="CD008738-sec-0179"> <h5 class="title">Worst case scenario analysis (considering dichotomous missing data as negative events)</h5> <p>The worst‐case scenario included 10 trials with incomplete outcome data (<a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a>; <a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>; <a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a>; <a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>) and found no significant differences with respect to the main analysis strategy. </p> </section> <section id="CD008738-sec-0180"> <h5 class="title">Statistical model for meta‐analysis</h5> <p>We performed a sensitivity analysis using a fixed‐effect model. Overall, there were no significant differences in the results for any outcome with respect to the analysis under the random‐effects model. As expected, the confidence intervals tended to be narrower when applying the fixed‐effect model, particularly for moderate and highly heterogeneous comparisons (i.e. I<sup>2</sup> = more than 50%) when no explanation for heterogeneity was found (e.g. clinical or pharmacological intervention, or population differences among trials). </p> </section> <section id="CD008738-sec-0181"> <h5 class="title">Analyses restricted to studies including participants with specific co‐morbidities</h5> <p>It was not possible to perform an analysis restricted to studies including participants with specific co‐morbidities because the vast majority of included trials did not report the co‐morbidities. Only two trials reported that eligible participants did not have any co‐morbidity (<a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>; <a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a>), and eight trials reported that they had included participants with co‐morbidities such as diabetes, kidney disease, liver dysfunction, immunodeficiency, massive obesity, or severe malnutrition (<a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a>; <a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>; <a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>; <a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0058" title="MillerL , HansbroughJ , SlaterH , GoldfarbIW , KealeyP , SaffleJ , et al. Sildimac: a new delivery system for silver sulfadiazine in the treatment of full‐thickness burn injuries. Journal of Burn Care and Rehabilitation 1990;11(1):35‐41. ">Miller 1990</a>; <a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a>; <a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a>). </p> </section> </section> <section id="CD008738-sec-0182"> <h4 class="title">Reporting bias</h4> <p>We were able to evaluate the possibility of publication bias in only one comparison, topical antibiotic prophylaxis.  We produced a funnel plot for burn wound infection including twenty‐six trials with five comparisons. We found symmetry in this plot and, therefore, we did not detect evidence of publication bias. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008738-sec-0183" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008738-sec-0183"></div> <p>This systematic review summarizes the best available evidence on the effects of antibiotic prophylaxis in people with burn wounds. Thirty‐six randomised controlled trials with a total of 2117 participants met the eligibility criteria for the review. The results were analysed according to the following groups: 1) topical antibiotic prophylaxis; 2) systemic antibiotic prophylaxis (general); 3) systemic antibiotic prophylaxis (perioperative); 4) non‐absorbable antibiotics (selective decontamination of the digestive tract); 5) local antibiotic prophylaxis (administered by airway); and 6) any antibiotic prophylaxis versus control. </p> <section id="CD008738-sec-0184"> <h3 class="title" id="CD008738-sec-0184">Summary of main results</h3> <section id="CD008738-sec-0185"> <h4 class="title">Efficacy of antibiotic prophylaxis</h4> <section id="CD008738-sec-0186"> <h5 class="title">1. Topical antibiotic prophylaxis</h5> <p>Overall there is no evidence that the use of prophylactic, topical antibiotics (compared with other topical preparations, dressings, placebo or no treatment_ reduces the risk of burn wound infection, invasive infections (pneumonia, bacteraemia, sepsis or UTI), or mortality associated with infection. Meta‐analysis of data from 11 RCTs indicates that participants treated with topical silver sulfadiazine (SSD) have a higher risk of burn wound infection than those treated with dressings/skin substitutes, although the trials included in this analysis had either a high or an unclear risk of bias. </p> <p>There is no evidence either that topical antibiotics have an influence on the secondary outcomes of this review. Generally time to wound healing was poorly analysed (as a continuous outcome rather than a time to event outcome) in the trials identified so it is difficult to judge the impact of the interventions on burn healing time. The average length of hospital stay (LOS) was significantly longer in participants whose burns were treated with SSD compared with dressings or skin substitute. </p> </section> <section id="CD008738-sec-0187"> <h5 class="title">2. Systemic antibiotic prophylaxis in the non‐surgical patient</h5> <p>There is no evidence that general systemic antibiotic prophylaxis compared with placebo or no active treatment has an influence on any of the primary outcome variables assessed (burn wound infection, sepsis, bacteraemia, UTI, or death associated with infection). The only clear benefit was a reduction in the incidence of pneumonia with TMP‐SMX compared with placebo, however, this was obtained from a small trial (40 participants) with an uncertain risk of bias (<a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>). Additionally, it was supported by Shionogi Pharmaceutical Company, which provided technical assistance in the measurement of TMP‐SMX concentrations. There is no evidence that systemic antibiotic prophylaxis has an effect on the secondary outcomes of this review. </p> </section> <section id="CD008738-sec-0188"> <h5 class="title">3. Perioperative systemic antibiotic prophylaxis</h5> <p>There is no evidence that perioperative systemic antibiotic prophylaxis compared with placebo or another antibiotic influences any of the outcome variables of this review (primary or secondary). </p> </section> <section id="CD008738-sec-0189"> <h5 class="title">4. Selective decontamination of the digestive tract (SDD)</h5> <p>There is no evidence that selective digestive tract decontamination (SDD) influences the frequency of burn wound infection, sepsis, or bacteraemia. Evidence indicates, however, that people in the SDD group developed more adverse events (diarrhoea) compared with those receiving placebo (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>). With regard to secondary outcomes, one study suggested that the number of participants who developed MRSA infection was higher in the SDD group than in the placebo group and LOS stay was greater in participants treated with SDD than in those who received placebo (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>). </p> </section> <section id="CD008738-sec-0190"> <h5 class="title">5. Local antibiotic prophylaxis (administered by airway)</h5> <p>There is no evidence that gentamicin administered by airway influences on the frequency of sepsis or total mortality when compared to placebo. </p> </section> </section> <section id="CD008738-sec-0191"> <h4 class="title">Safety of antibiotic prophylaxis</h4> <p>In general, it could not be demonstrated that antibiotic prophylaxis is associated with an increase in adverse events in any of the comparisons, except for one study that suggested an increased frequency in people receiving SDD compared to those receiving placebo (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>).It should be noted that adverse events were poorly reported. </p> </section> </section> <section id="CD008738-sec-0192"> <h3 class="title" id="CD008738-sec-0192">Overall completeness and applicability of evidence</h3> <p>Despite the fact that during recent years several measures to improve care of burn patients have been implemented, treating burn wounds continues to be a complex process. With the establishment of early excision of damaged tissue, skin grafts, and the strict implementation of infection‐control measures in burn‐care centres, it has been possible to reduce bacterial resistance, though not the incidence of infections. Topic application of SSD has shown a higher risk of burn wound infection and an increased length of hospital stay. </p> <p>The results given in this review are still limited; few data could be pooled in most comparisons. Outcome measures and follow‐up times were heterogeneous, or not even defined, which made it difficult to interpret the results of the review and to determine their applicability. These results, however, will undoubtedly evolve with the establishment of new strategies and the standardization of care for burn wounds. As a result of these factors, it was not possible to identify or generate definitive evidence on the effects of antibiotic prophylaxis in people with burn wounds. </p> </section> <section id="CD008738-sec-0193"> <h3 class="title" id="CD008738-sec-0193">Quality of the evidence</h3> <p>Overall, the risk of bias of the studies was high or uncertain, and many had small sample sizes. Consequently, there is little evidence about the effects of antibiotic prophylaxis in people with burn wounds. Many of the key methodological aspects considered in the risk of bias tool were not described in the reports of the studies (or were not presented with sufficient information to allow their evaluation). Most of the studies did not follow the recommendations of the CONSORT statement (<a href="./references#CD008738-bbs2-0110" title="MoherD ,  SchulzKF ,  AltmanD ,  CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285(15):1987‐91. ">Moher 2001</a>), even when they were published after 2001 ‐ the year in which the CONSORT statement was published. </p> <p>Only one study presented a low risk of selection bias (i.e. used adequate methods to generate a random allocation sequence and to conceal this sequence) (<a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a>), however, this study had only 23 participants. Only seven studies adequately described the methods used to generate the random sequence (and were deemed appropriate), and only four studies adequately described the methods used to conceal the sequence (and were deemed appropriate). Often, there was not enough information to assess the blinding of the study, or whether participants had been blinded. A key methodological point in this kind of study is blinding the person in charge of measuring outcomes, but most of the included studies did not report whether this was done. Loss of participants in the included studies was generally low, although the sample sizes for many of them were small. Most studies did not explain if, or how, the sample size was predetermined. Another key methodological aspect of some of the included studies was using more than one burn wound per participant (<a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>; <a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a>; <a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>; <a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a>; <a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a>; <a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a>). In these cases, the strategies of analysis implemented were inadequate, because they did not take into account the methodological peculiarities of such designs. </p> <p>There was a high degree of heterogeneity between studies in terms of interventions evaluated, types of burn, and outcomes assessed. This made it difficult to determine the effectiveness of antibiotic prophylaxis. </p> <p>We evaluated the possibility of publication bias for one of the comparisons and one of the outcome measures, namely topical antibiotic prophylaxis and burn wound infection, respectively (Figure 4). The figure included twenty‐five trials with five comparisons. Given that this graph displayed symmetry, we did not detect evidence that suggested publication bias. </p> </section> <section id="CD008738-sec-0194"> <h3 class="title" id="CD008738-sec-0194">Potential biases in the review process</h3> <p>Publication bias is a major threat to the validity of systematic reviews. To minimize the risk of publication bias, we conducted an exhaustive search across numerous clinical trial databases. Nonetheless, as for any systematic review, we cannot rule out distortion of the results by publication bias. </p> <p>Some studies reported the mean time to healing in each group, but did not provided complete data for time‐to‐event analysis. Only one trial reported outcome measures with hazard ratio (HR), therefore, we could not pool the trial data to estimate the hazard ratio. Also, the lack of information regarding the standard deviation around the mean in several trials, did not allow us to perform a pooled estimation of mean difference. This may have hindered the consideration of all relevant information available for the outcome of 'time to wound healing'. </p> </section> <section id="CD008738-sec-0195"> <h3 class="title" id="CD008738-sec-0195">Agreements and disagreements with other studies or reviews</h3> <p>There have been a number of other systematic reviews in the field although none precisely overlaps with ours in focus. </p> <p>The review by <a href="./references#CD008738-bbs2-0078" title="AvniT , LevcovichA , Ad‐ElDD , LeiboviciL , PaulM . Prophylactic antibiotics for burns patients: systematic review and meta‐analysis. BMJ2010;340:c241. ">Avni 2010</a> also evaluated the effect of antibiotic prophylaxis in people with burn wounds. This review differed from ours with respect to the inclusion criteria for the studies, and to the methodology. One of the main differences was that <a href="./references#CD008738-bbs2-0078" title="AvniT , LevcovichA , Ad‐ElDD , LeiboviciL , PaulM . Prophylactic antibiotics for burns patients: systematic review and meta‐analysis. BMJ2010;340:c241. ">Avni 2010</a> considered mortality from any cause as the main outcome, and bacteraemia, pneumonia, and burn wound infection as secondary outcomes. <a href="./references#CD008738-bbs2-0078" title="AvniT , LevcovichA , Ad‐ElDD , LeiboviciL , PaulM . Prophylactic antibiotics for burns patients: systematic review and meta‐analysis. BMJ2010;340:c241. ">Avni 2010</a> agreed with the results of our review when suggesting that systemic antibiotic prophylaxis (general or perioperative) may reduce the incidence of pneumonia (RR = 0.55; 95% CI: 0.36 to 0.84, three trials) and all‐cause mortality (RR = 0.54; 95% CI: 0.34 to 0.87, five trials). This review suggests that non‐absorbable antibiotics do not significantly affect mortality, however, <a href="./references#CD008738-bbs2-0078" title="AvniT , LevcovichA , Ad‐ElDD , LeiboviciL , PaulM . Prophylactic antibiotics for burns patients: systematic review and meta‐analysis. BMJ2010;340:c241. ">Avni 2010</a> concluded that systemic antibiotic prophylaxis applied perioperatively may have a beneficial effect in reducing burn wound infection, which disagrees with the results of our review. <a href="./references#CD008738-bbs2-0078" title="AvniT , LevcovichA , Ad‐ElDD , LeiboviciL , PaulM . Prophylactic antibiotics for burns patients: systematic review and meta‐analysis. BMJ2010;340:c241. ">Avni 2010</a> found the risk of bias of trials was high. </p> <p>The systematic review by <a href="./references#CD008738-bbs2-0100" title="LeeF , WongP , HillF , BurgnerD , TaylorR . Evidence behind the WHO guidelines: Hospital care for children: What is the role of prophylactic antibiotics in the management of burns?. Journal of Tropical Pediatrics2009;55(2):73‐7. ">Lee 2009</a>, suggests that the available evidence does not justify the use of general systemic antibiotic prophylaxis in the management of burn wounds in children, we cannot confirm this as we did not have data on children. <a href="./references#CD008738-bbs2-0100" title="LeeF , WongP , HillF , BurgnerD , TaylorR . Evidence behind the WHO guidelines: Hospital care for children: What is the role of prophylactic antibiotics in the management of burns?. Journal of Tropical Pediatrics2009;55(2):73‐7. ">Lee 2009</a>, however, mentions that currently there are topical antimicrobial agents that guarantee lower rates of colonization and infection ‐ a claim that does not correspond the results of our review. </p> <p>The review by <a href="./references#CD008738-bbs2-0132" title="WasiakJ , ClelandH , CampbellF . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD002106.pub3] ">Wasiak 2008</a> studied the effects of wound dressings rather than antibiotics and was focused only on superficial and partial thickness burns, whereas our review included studies of people with burns of any severity. Another key difference between <a href="./references#CD008738-bbs2-0132" title="WasiakJ , ClelandH , CampbellF . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD002106.pub3] ">Wasiak 2008</a> and our review is our primary focus on infection, mortality and adverse events as primary outcomes rather than wound healing. Nevertheless we reached the same conclusion as </p> <p><a href="./references#CD008738-bbs2-0132" title="WasiakJ , ClelandH , CampbellF . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD002106.pub3] ">Wasiak 2008</a> regarding SSD; they concluded that dressings impregnated with SSD decrease the healing of burn wounds; these results were confirmed by our review, which is based on a greater number of studies. </p> <p><a href="./references#CD008738-bbs2-0094" title="HoogewerfCJ , VanBaarME , HopMJ , NieuwenhuisMK , OenIMMH , MiddelkoopE . Topical treatment for facial burns. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD008058.pub2] ">Hoogewerf 2013</a> assessed the effects of topical interventions for wound healing on facial burns and therefore the eligibility criteria defined are somewhat different from ours. <a href="./references#CD008738-bbs2-0094" title="HoogewerfCJ , VanBaarME , HopMJ , NieuwenhuisMK , OenIMMH , MiddelkoopE . Topical treatment for facial burns. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD008058.pub2] ">Hoogewerf 2013</a> concluded that “there is insufficient reliable evidence as to whether topical treatments improve outcomes for people with facial burns including improved wound healing, rates of infection, the need for surgery...". Our findings echo this; there is a relative lack of evidence for the effects of the prophylactic use of topical antibiotics in people with burns (as compared to other topical treatments, placebo or no treatment), due to the volume and quality of the existing research. </p> <p>The systematic review by <a href="./references#CD008738-bbs2-0122" title="RosanovaMT ,  StamboulianD ,  LedeR . Systematic review: which topical agent is more efficacious in the prevention of infections in burn patients? [Revisión sistemática: ¿Cuál es el agente tópicomás eficaz en la prevención de infeccionesen el paciente quemado?]. Archivos Argentinos de Pediatría2012;110(4):298‐303. ">Rosanova 2012</a>compared different topical agents for preventing burn wound infections. <a href="./references#CD008738-bbs2-0122" title="RosanovaMT ,  StamboulianD ,  LedeR . Systematic review: which topical agent is more efficacious in the prevention of infections in burn patients? [Revisión sistemática: ¿Cuál es el agente tópicomás eficaz en la prevención de infeccionesen el paciente quemado?]. Archivos Argentinos de Pediatría2012;110(4):298‐303. ">Rosanova 2012</a> included both randomised and quasi‐randomised trials, and considered infections and sepsis as primary outcomes. This review concluded that there is no evidence to prove the superiority of any one topical agent to reduce infection or sepsis in the burn patient. Our review supports these conclusions. </p> <p>Finally our review is in broad agreement with recommendations made by recent clinical practice guidelines on the management of burn wounds, which do not recommend antibiotic prophylaxis for the prevention of infection in the burned person (<a href="./references#CD008738-bbs2-0074" title="AlsbjörnB , GilbertP , HartmannB , KaźmierskiM , MonstreyS , PalaoR , et al. Guidelines for the management of partial‐thickness burns in a general hospital or community setting recommendations of a European working party. Burns2007;33(2):155‐60. ">Alsbjörn 2007</a>; <a href="./references#CD008738-bbs2-0081" title="BrychtaP , MagnetteA .  . European Practice Guidelines for Burn Care. The Netherlands, 2011. ">Brychta 2011</a><i>;</i><a href="./references#CD008738-bbs2-0095" title="HospenthalDR ,  MurrayCK ,  AndersenRC ,  BellRB ,  CalhounJH ,  CancioLC , et al. Guidelines for the prevention of infections associated with combat‐related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. Journal of Trauma2011;71(Suppl 2):S210‐34. ">Hospenthal 2011</a>; <a href="./references#CD008738-bbs2-0114" title="NSW Severe Burn Injury Service (SBIS). Clinical Practice Guidelines Burn Wound Management. New South Wales, 2008. ">NSW Severe Burn Injury Service 2008</a>; <a href="./references#CD008738-bbs2-0136" title="Work Loss Data Institute (WLDI). Burns. Corpus Christi, Texas, 2008. ">WLDI 2008</a>). In contrast the New Zealand Guidelines Group (<a href="./references#CD008738-bbs2-0115" title="New Zealand Guidelines Group (NZGG). Management of burns and scalds in primary care. Wellington, NZ., 2007. ">NZGG 2007</a>) recommended the use of products with antimicrobial action (such as silver sulphadiazine cream) on all burns for the first 72 hours (three days) after burn injury. However the New Zealand guideline clearly stated that there was little evidence supporting the use of silver sulphadiazine for non‐infected burns, and that the recommendation for its routine use during the first three days was supported only by clinical experience in New Zealand populations, specifically by the high incidence of community‐acquired Staphylococcus aureus sepsis (<a href="./references#CD008738-bbs2-0106" title="MilesF , VossL , SegedinE , AndersonBJ . Review of Staphylococcus aureus infections requiring admission to a paediatric intensive care unit. Archives of Disease in Childhood2005;90(12):1274‐8. ">Miles 2005</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008738-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008738-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008738-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD008738-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 1 Burn wound infection." data-id="CD008738-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 1 Burn wound infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 2 Infections in the burned people (sepsis)." data-id="CD008738-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 2 Infections in the burned people (sepsis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 3 Infections in burned people (bacteraemia)." data-id="CD008738-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 3 Infections in burned people (bacteraemia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 4 Infections in burned people (pneumonia)." data-id="CD008738-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 4 Infections in burned people (pneumonia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 5 Infections in burned people (urinary tract infection)." data-id="CD008738-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 5 Infections in burned people (urinary tract infection). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 6 Adverse events." data-id="CD008738-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 7 Infection‐related mortality." data-id="CD008738-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 7 Infection‐related mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 8 Antibiotic resistance (MRSA)." data-id="CD008738-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 8 Antibiotic resistance (MRSA).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 9 All‐cause mortality." data-id="CD008738-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 9 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical antibiotic prophylaxis, Outcome 10 Length of hospital stay (LOS)." data-id="CD008738-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Topical antibiotic prophylaxis, Outcome 10 Length of hospital stay (LOS).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 1 Burn wound infection." data-id="CD008738-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 1 Burn wound infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 2 Infections in burned people (sepsis)." data-id="CD008738-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 2 Infections in burned people (sepsis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 3 Infections in burned people (bacteraemia)." data-id="CD008738-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 3 Infections in burned people (bacteraemia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 4 Infections in burned people (pneumonia)." data-id="CD008738-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 4 Infections in burned people (pneumonia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 5 Infections in burned people (urinary tract infection)." data-id="CD008738-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 5 Infections in burned people (urinary tract infection). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 6 Infection‐related mortality." data-id="CD008738-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 6 Infection‐related mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 7 Antibiotic resistance (MRSA)." data-id="CD008738-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 7 Antibiotic resistance (MRSA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 8 All‐cause mortality." data-id="CD008738-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 8 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 9 Length of hospital stay (LOS)." data-id="CD008738-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Systemic antibiotic prophylaxis (general), Outcome 9 Length of hospital stay (LOS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 1 Burn wound infection." data-id="CD008738-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 1 Burn wound infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 2 Infections in burned people (bacteraemia)." data-id="CD008738-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 2 Infections in burned people (bacteraemia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 3 Infections in burned people (pneumonia)." data-id="CD008738-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 3 Infections in burned people (pneumonia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 4 Infections in burned people (urinary tract infection)." data-id="CD008738-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 4 Infections in burned people (urinary tract infection). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 5 Adverse events." data-id="CD008738-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 6 All‐cause mortality." data-id="CD008738-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 6 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 7 Length of hospital stay (LOS)." data-id="CD008738-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Systemic antibiotic prophylaxis (perioperative), Outcome 7 Length of hospital stay (LOS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 1 Burn wound infection." data-id="CD008738-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 1 Burn wound infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 2 Infections in burned people (sepsis)." data-id="CD008738-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 2 Infections in burned people (sepsis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 3 Infections in burned people (bacteraemia)." data-id="CD008738-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 3 Infections in burned people (bacteraemia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 4 Infections in burned people (pneumonia)." data-id="CD008738-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 4 Infections in burned people (pneumonia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 5 Infections in burned people (urinary tract infection)." data-id="CD008738-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 5 Infections in burned people (urinary tract infection). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 6 Adverse events." data-id="CD008738-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 7 Antibiotic resistance (MRSA)." data-id="CD008738-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 7 Antibiotic resistance (MRSA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 8 All‐cause mortality." data-id="CD008738-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 8 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 9 Length of hospital stay (LOS)." data-id="CD008738-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract), Outcome 9 Length of hospital stay (LOS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Local antibiotic prophylaxis (airway), Outcome 1 Infections in burned people (sepsis)." data-id="CD008738-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Local antibiotic prophylaxis (airway), Outcome 1 Infections in burned people (sepsis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Local antibiotic prophylaxis (airway), Outcome 2 All‐cause mortality." data-id="CD008738-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Local antibiotic prophylaxis (airway), Outcome 2 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 1 Burn wound infection." data-id="CD008738-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 1 Burn wound infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 2 Infections in burned people (sepsis)." data-id="CD008738-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 2 Infections in burned people (sepsis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 3 Infections in burned people (bacteraemia)." data-id="CD008738-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 3 Infections in burned people (bacteraemia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 4 Infections in burned people (pneumonia)." data-id="CD008738-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 4 Infections in burned people (pneumonia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 5 Infections in burned people (urinary tract infection)." data-id="CD008738-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 5 Infections in burned people (urinary tract infection). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 6 Infection‐related mortality." data-id="CD008738-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 6 Infection‐related mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 7 Adverse events." data-id="CD008738-fig-0047" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 8 Antibiotic resistance (MRSA)." data-id="CD008738-fig-0048" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 8 Antibiotic resistance (MRSA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 9 All‐cause mortality." data-id="CD008738-fig-0049" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 9 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008738-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/urn:x-wiley:14651858:media:CD008738:CD008738-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_t/tCD008738-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 10 Length of hospital stay (LOS)." data-id="CD008738-fig-0050" src="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Antibiotic prophylaxis vs control/placebo, Outcome 10 Length of hospital stay (LOS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/media/CDSR/CD008738/image_n/nCD008738-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008738-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Definition of the outcomes assessed</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study‐Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Wound infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sepsis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Bacteraemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Pneumonia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Urinary tract infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Adverse events </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Time to complete healing </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0001" title="AlexanderJW , MacMillanBG , LawEJ , KrummelR . Prophylactic antibiotics as an adjunct for skin grafting in clean reconstructive surgery following burn injury. Journal of Trauma1982;22(8):687‐90. ">Alexander 1982</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discharge of pus in the graft site, associated with graft loss.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event related to the administration of the antibiotic or the placebo. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0002" title="AlexanderJW , MacMillanBG , LawEJ , KernR . Lack of beneficial effects of restricted prophylactic antibiotics for debridement and/or grafting of seriously burned patients. Bulletin and Clinical Review of Burn Injuries1984;1:20. ">Alexander 1984</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define bacteraemia, but assessed the total number of episodes of bacteraemia per days at risk </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical evaluation (presence of fever and/or redness of the wound) and qualitative bacteriological examination of samples from the wound. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bacterial infection was evaluated by bacteriological examination of blood.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of respiratory infection was determined by qualitative bacteriological examination of sputum. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined the presence of urinary tract infection by qualitative bacteriological examination of urine. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wound was declared healed when 75% of the total surface had healed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined BWI through the assessment of clinical data.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define bacteraemia, but reported data on this result.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined wound cicatrisation as closing of all affected areas in the initial wound.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burn wound biopsy with more than 10<sup>5</sup> organism/g<br/> tissue and/or histologic evidence of viable tissue<br/> invasion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of a septic source: (1) burn wound biopsy with more than 10<sup>5</sup> organism/g<br/> tissue and/or histologic evidence of viable tissue<br/> invasion, (2) positive blood culture, (3) urinary tract infection with 10<sup>5</sup> organism/ml urine; and (4) pulmonary infection with positive bacteria and white<br/> cells on a class III, or better sputum specimen. </p> <p>In addition to the identification of a septic source, five or more of the following criteria had to be met: tachypnoea<br/> (&gt; 40 breaths/minute); prolonged paralytic ileus;<br/> hyper‐ or hypothermia (&lt; 36.5°C or &gt; 38.5°C); altered<br/> mental status; thrombocytopenia (&lt; 50 000 platelets/mm<sup>3</sup>); leucocytosis or leukopenia (&lt; 3.5 or &gt; 15.0 cells/mm<sup>3</sup>); unexplained acidosis; or hyperglycaemia. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary infection with positive bacteria and white<br/> cells on a class III, or better sputum specimen. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but registered diverse complication.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported time to complete healing.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this result.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported allergies and bleeding as adverse events.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A wound was considered cicatrised when it had healed completely.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this result.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any new adverse event (including infection) or any adverse event that had worsened during the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A wound was considered cicatrised when there was 100% re‐epithelisation, including the small residual crusts, blisters and open areas of &lt; 1 cm in an area that had been re‐epithelialized completely.    </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0008" title="De LaCalMA , CerdáE , García‐HierroP , vanSaeneHK , Gómez‐SantosD , NegroE , et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo‐controlled, double‐blind trial. Annals of Surgery2005;241(3):424‐30. ">De La Cal 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI determined by microbiological testing of samples from the surface of the wound, performed upon admission and then twice a week. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bloodstream infections<br/> were diagnosed according to CDC definitions for nosocomial<br/> infections. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of new (or<br/> progressive) pulmonary infiltrates persisting for &gt; 48 h on chest X‐ray, in addition to at least 2 of the following<br/> criteria: (1) fever ≥ 38.5°C or hypothermia &lt; 35.0°C; (2) leucocytosis ≥ 10,000/mm<sup>3</sup> or leukopenia &lt; 3000/mm<sup>3</sup>;<br/> (3) isolation of potential pathogens in high concentration of<br/> ≥ 4 x 10<sup>7</sup> cfu/ml using semi quantitative<br/> culture, from unprotected purulent tracheal aspirates. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary tract infections<br/> were diagnosed according to CDC definitions for nosocomial<br/> infections. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI determined by clinical assessment of signs (increased exudate and surrounding cellulitis). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the wounds were healed when re‐epithelialization had reached ≥ 90%.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Accepted quantitative culture of samples from the wound as evidence of infection.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the wounds were healed when re‐epithelialization had reached 95%.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0011" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HenrdonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521‐4. ">Desai 1991</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined BWI through the clinical evaluation of signs and symptoms.  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0012" title="DurtschiMB , OrgainC , CountsGW , HeimbachDM . A prospective study of prophylactic penicillin in acutely burned hospitalized patients. Journal of Trauma1982;22(1):11‐4. ">Durtschi 1982</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wound infection was considered when had cellulitis. The cellulitis was clinically defined as an area of warm, spreading, cutaneous erythema, accompanied by local pain and fever. Cellulite was determined by positive culture of samples from the surface of the wound. </p> <p>The samples for the culture were taken upon admission, and the samples for follow‐up, at days 5 and 7.  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syndrome resulting from the presence<br/> of &gt; 100,000 organisms/g biopsied wound tissue, associated with variable temperature and<br/> leucocyte count, blood chemistry abnormalities, and occasionally ‐ but not invariably ‐ accompanied by positive blood cultures. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define bacteraemia, but reported data on bacteraemia by beta‐haemolytic streptococcal.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define urinary tract infection, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the presence of "local purulence" constituted infection. Additionally, accepted a positive bacterial culture of wound samples as proof of infection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define the term sepsis, but reported patients who had presented with purulence with septicaemia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of systemic disease.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported time to healing.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection determined by semi‐quantitative cultures of surface samples.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Completely re‐epithelialized wounds. Wounds considered to be treatment failures if had not healed within 21  days or had required skin grafts. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healing time defined as the time required to achieve full epithelialisation of the burned surface. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0016" title="GlatPM , KubatWD , HsuJF , CoptyT , BurkeyBA , DavisW , et al. Randomized clinical study of SilvaSorb gel in comparison to Silvadene silver sulfadiazine cream in the management of partial‐thickness burns. Journal of Burn Care and Research2009;30(2):262‐67. ">Glat 2009</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined BWI through the assessment of clinical data.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on possible adverse effects.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection determined by semi‐quantitative cultures of wound surface samples.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on adverse reactions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not report the definition of cicatrisation, but assessed the percentage of wound healing at different times, up to 21 days and to the time healing.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI defined by the presence of clinical data in conjunction with cultures from the wound surface. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported time to healing.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection determined by semi‐quantitative cultures of wound surface samples.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the wounds were healed when re‐epithelialization had reached 95%‐100%.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0020" title="HosseiniSN , KarimianA , MousavinasabSN , RahmanpourH , YaminiM , ZahmatkeshSH . Xenoderm versus 1% silver sulfadiazine in partial‐thickness burns. Asian Journal of Surgery2009;32(4):234‐9. ">Hosseini 2009</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined BWI through the assessment of clinical data.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0022" title="KimuraA , MochizukiT , NishizawaK , MashikoK , YamamotoY , OtsukaT . Trimethoprim‐sulfamethoxazole for the prevention of methicillin‐resistant Staphylococcus aureus pneumonia in severely burned patients. Journal of Trauma1998;45(2):383‐7. ">Kimura 1998</a>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients satisfying all of the following criteria: (1) infiltration of lung fields on chest X‐ray films;<br/> (2) fever (&gt; 38°C) for at least 3 consecutive days; </p> <p>(3) peripheral<br/> white blood cell count &gt; 10<sup>4</sup>/mm<sup>3</sup>. </p> <p>(4) Pathogenic<br/> bacteria (&gt; 10<sup>3</sup> cfu/ml) detected in airway<br/> secretions. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but assessed the associated secondary effects during the period of antibiotic administration. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define urinary tract infection but reported data on this outcome.</p> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined by clinical assessment</p> <p>of the wound</p> <p>(assessment of the nature of epithelialization ‐ percentage and healing time). </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0023" title="LevineBA , PetroffPA , SladeCL , PruittBAJr . Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. Journal of Trauma1978;18(3):188‐93. ">Levine 1978</a>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define sepsis, but reported that blood cultures were performed three times a week and upon suspicion of sepsis. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0024" title="LivingstonDH , CryerHG , MillerFB , MalangoniMA , PolkHCJr , WeinerLJ . A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. Plastic and Reconstructive Surgery1990;86(6):1059‐64; discussion 1065. ">Livingston 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>More than 10<sup>5</sup> organisms/g of<br/> tissue in both the nonadherent graft and recipient<br/> site. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define sepsis, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0025" title="MayaBJ , CovarrubiasBA , RomeroPA , LiconaVL , ClaessonBE , FilipssonS , et al. Spray rifamycin and amniotic membranes in second degree burns [Rifamicina spray y membranas amnióticas en quemaduras de segundo grado]. Compendium de Investigaciones Clinicas Latinoamericanas1986;6(2):73‐80. ">Maya 1986</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI determined by daily assessment of signs and symptoms.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0026" title="MillerLM , CarbollWB , HansbroughJF . The effect of antimicrobial prophylaxis for burn wound excision: Ceforanide versus cefazolin. Current Therapeutic Research, Clinical and Experimental1987;41(6):946‐51. ">Miller 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined wound infection as cellulitis.</p> <p>Bacterial cultures were performed when there was suspicion of infection and at the end of the study. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define pneumonia, but reported data on this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define urinary tract infection, but reported data on this outcome. Conducted routine urine analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on adverse reactions.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0027" title="MohammadiAA , RiaziH , HasheminasabMJ , SabetB , MohammadiMK , AbbasiS , et al. Amniotic membrane dressing vs conventional topical antibiotic dressing in hospitalized burn patients. Iranian Red Crescent Medical Journal2009;11(1):66‐70. ">Mohammadi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined wound infection through the  daily evaluation of signs and symptoms.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>When there were symptoms and signs of hypothermia,<br/> hypotension, abrupt hyperglycaemia, decreased urine output, thrombocytopenia and diet intolerance, a thorough check‐up including blood culture and urine culture was done. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported data on time to healing.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0029" title="MuangmanP , ChuntrasakulC , SilthramS , SuvanchoteS , BenjathanungR , KittidachaS , et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial‐thickness burn wounds. Journal of The Medical Association of Thailand2006;89(7):953‐8. ">Muangman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined wound infection by clinical data in conjunction with cultures from the wound surface. </p> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0030" title="MunsterAM , WinchurchRA , ThupariJN , ErnstCB . Reversal of postburn immunosuppression with low‐dose polymyxin B. Journal of Trauma1986;26(11):995‐8. ">Munster 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of clinical data together with burn wound biopsy with &gt; 10<sup>5</sup> organisms/g<br/> tissue. Biopsies were taken twice a week. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined sepsis through two parameters: (1) presence of a positive blood culture, and the presence or absence of standard signs of sepsis such as hypothermia, disorientation and paralytic ileus; or (2) presence of a quantitative biopsy on one or more occasions of ≥ 10<sup>5</sup> organisms coupled with any of the clinical parameters mentioned above. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on possible adverse effects.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that wounds were healed when there had been epithelial closing of 90% of the site of the wound. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0032" title="RodgersGL , FisherMC , LoA , CresswellA , LongSS . Study of antibiotic prophylaxis during burn wound debridement in children. Journal of Burn Care and Rehabilitation1997;18(4):342‐6. ">Rodgers 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWI determined by quantitative culture of tissue biopsies. Performed colony count; results expressed as cfu/g of tissue. </p> <p>A culture was considered positive when growth was more than 10<sup>5</sup> cfu/g of tissue.  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define bacteraemia, but reported data on this outcome. Blood cultures were performed for the isolation and identification of pathogenic organisms. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0033" title="SilverGM , RobertsonSW , HalerzMM , ConradP , SuppleKG , GamelliRL . A silver‐coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. Journal of Burn Care and Research2007;28(5):715‐9. ">Silver 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define BWI, but reported data on this outcome.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on possible adverse effects.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define adverse events, but reported data on this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Determined that the wounds were healed when there was a new layer of epithelium.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0035" title="SubrahmanyamM . A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. Burns1998;24(2):157‐61. ">Subrahmanyam 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presence of burn wound biopsy with &gt; 10<sup>5</sup> organisms/g<br/> tissue. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined wound infection through the  evaluation of clinical data.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse effects related to medication (allergic or hypersensitivity reactions) or a worsening of symptoms or complications (infection, wound infection). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not define cicatrisation, but reported data on time to healing.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>Abbreviations</b> </p> <p>&lt; = less than<br/> &gt; = more than<br/> ≥ = more than or equal to<br/> BWI = burn wound infection<br/> CDC = Centers for Disease Control<br/> cfu = colony forming units<br/> h = hour(s) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Definition of the outcomes assessed</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008738-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Time to complete wound healing</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study or Subgroup</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>P value</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hazard Ratio</b> </p> <p><b>(HR)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Neomycin, bacitracin and polymyxin B vs control/placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Silver sulfadiazine vs polymyxin B/bacitracin</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0034" title="SoroffHS , SasvaryDH . Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial‐thickness burns: a pilot study. Journal of Burn Care and Rehabilitation 1994;15(1):13‐7. ">Soroff 1994</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.0007</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Silver sulfadiazine vs dressings (skin substitute)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0004" title="BarretJP , DziewulskiP , RamzyPI , WolfSE , DesaiMH , HerndonDN . Biobrane versus 1% silver sulfadiazine in second‐degree pediatric burns. Plastic and Reconstructive Surgery2000;105(1):62‐5. ">Barret 2000</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0006" title="BugmannP , TaylorS , GygerD , LironiA , GeninB , VundaA , et al. A silicone‐coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns1998;24(7):609‐12. ">Bugmann 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0007" title="CarusoDM , FosterKN , Blome‐EberweinSA , TwomeyJA , HerndonDN , LutermanA , et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial‐thickness burns. Journal of Burn Care and Research2006;27(3):298‐309. ">Caruso 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.517</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0014" title="GerdingRL , ImbemboAL , FratianneRB . Biosynthetic skin substitute vs 1% silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. Journal of Trauma1988;28(8):1265‐9. ">Gerding 1988</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0015" title="GerdingRL , EmermanCL , EffronD , LukensT , ImbemboAL , FratianneRB . Outpatient management of partial‐thickness burns: Biobrane versus 1% silver sulfadiazine. Annals of Emergency Medicine1990;19(2):121‐4. ">Gerding 1990</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0017" title="GongZ‐H , YaoJ , JiJ‐F , YangJ , XiangT . Effect of ionic silver dressing combined with hydrogel on degree II burn wound healing [in Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(42):8373‐6. ">Gong 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0018" title="GotschallCS , MorrisonMIS , EichelbergerMR . Prospective randomized study of the efficacy of Mepitel on children with partial‐thickness scalds. Journal of Burn Care and Rehabilitation1998;19(4):279‐83. ">Gotschall 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.0002</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0031" title="NoordenbosJ , DoreC , HansbroughJF . Safety and efficacy of TransCyte for the treatment of partial‐thickness burns. Journal of Burn Care and Rehabilitation1999;20(4):275‐81. ">Noordenbos 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.002</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0036" title="TayadeMB , BakhshiGD , HaobijamN . A comparative study of collagen sheet cover versus 1% silver sulphadiazine in partial thickness burns. Bombay Hospital Journal2006;48(2):http://www.bhj.org/journal/2006_4802_april/html/org_res_263‐267.html. ">Tayade 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Silver sulfadiazine vs any topical preparation of natural products (traditional medicine)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0003" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face ‐ experience with the use of moist exposed burn ointment (MEBO)compared with silver sulphadiazine. Annals of the Academy of Medicine2002;29(1):7‐10. AngES , LeeST , GanCS , SeePG , ChanYH , NgLH , et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second‐degree burns. Medscape General Medicine2001;3(12):3‐18. ">Ang 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0021" title="KhorasaniG , HosseinimehrSJ , AzadbakhtM , ZamaniA , MahdaviMR . Aloe versus silver sulfadiazine creams for second‐degree burns: A randomized controlled study. Surgery Today2009;39(7):587‐91. ">Khorasani 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.0001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0028" title="MoharamzadY , PanahiY , BeiraghdarF , FeiziI . Focused Conference Group: P16 ‐ Natural products: Past and future? Clinical efficacy of a topical herbal cream (Aloe vera, Geranium robertianum and Lavandula stoechas) in second‐degree burn wounds. Basic and Clinical Pharmacology and Toxicology2010;107(Suppl. 1):162–69. ">Moharamzad 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Topical antibiotic prophylaxis vs other treatments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0013" title="FisherAJ , MorrisonG , van derRiet RleS . A blind trial of two aerosol sprays in the exposure treatment of burns. South African Medical Journal 1968;42(34):903‐5. ">Fisher 1968</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0019" title="HauserJ , RossbachO , LangerS , VogtP , GermannG , SteinauHU , et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad‐IIa‐Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin‐Creme]. Unfallchirurg2007;110(11):988‐94. ">Hauser 2007</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value 0.015</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Other topical antibiotics vs dressings (skin substitute)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0009" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio‐engineered skin substitutes). Burns1999;25(3):256‐61. ">Demling 1999</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008738-bbs2-0010" title="DemlingRH , DeSantiL . The potential benefits of a temporary bioactive skin substitute to treat partial‐thickness burns of the feet. Wounds: A Compendium of Clinical Research and Practice2003;15(1):10‐5. ">Demling 2003</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value &lt; 0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Non‐absorbable antibiotic prophylaxis vs placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008738-bbs2-0005" title="BarretJP , JeschkeMG , HerndonDN . Selective decontamination of the digestive tract in severely burned pediatric patients. Burns2001;27(5):439‐45. ">Barret 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>Abbreviations</b> </p> <p>&lt; = less than<br/> vs = versus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Time to complete wound healing</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/full#CD008738-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008738-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical antibiotic prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Burn wound infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.02, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Neomycin, bacitracin and polymyxin B vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.32, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Silver sulfadiazine vs dressings or skin substitute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.09, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Silver sulfadiazine vs traditional medicine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.54, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Other topical antibiotics vs dressings or skin substitute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.19, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.94, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infections in the burned people (sepsis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Neomycin, bacitracin and polymyxin B vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.58 [0.44, 130.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.31 [1.61, 11.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Infections in burned people (bacteraemia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Neomycin, bacitracin and polymyxin B vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Silver sulfadiazine vs dressings or skin substitute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Silver sulfadiazine vs traditional medicine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infections in burned people (pneumonia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Neomycin, bacitracin and polymyxin B vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Silver sulfadiazine vs traditional medicine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infections in burned people (urinary tract infection) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Silver sulfadiazine vs traditional medicine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Silver sulfadiazine vs polymyxin B/bacitracin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Silver sulfadiazine vs dressings or skin substitute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.47, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Other topical antibiotics vs dressings or skin substitute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.05, 18.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 18.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Infection‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Neomycin, bacitracin and polymyxin B vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Silver sulfadiazine vs traditional medicine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Antibiotic resistance (MRSA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Neomycin, bacitracin and polymyxin B vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Silver sulfadiazine vs dressings or skin substitute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Silver sulfadiazine vs traditional medicine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Silver sulfadiazine vs dressings or skin substitute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Silver sulfadiazine vs traditional medicine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.17, 19.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.95 [1.10, 32.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Length of hospital stay (LOS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Neomycin, bacitracin and polymyxin B vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.67 [‐9.46, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Silver sulfadiazine vs dressings or skin substitute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.93, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Antibiotic prophylaxis vs other treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [1.45, 5.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical antibiotic prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008738-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Systemic antibiotic prophylaxis (general)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Burn wound infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.07, 6.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infections in burned people (sepsis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.12, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Infections in burned people (bacteraemia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infections in burned people (pneumonia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infections in burned people (urinary tract infection) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Infection‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.05, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Antibiotic resistance (MRSA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.17, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Length of hospital stay (LOS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Systemic antibiotic prophylaxis (general)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008738-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Systemic antibiotic prophylaxis (perioperative)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Burn wound infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.03, 7.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Cephazolin vs other antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.49, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infections in burned people (bacteraemia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.31, 5.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Cephazolin vs other antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.28, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Infections in burned people (pneumonia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cephazolin vs other antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infections in burned people (urinary tract infection) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cephazolin vs other antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Cephazolin vs other antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Length of hospital stay (LOS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Systemic antibiotic prophylaxis (perioperative)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008738-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Burn wound infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Non‐absorbable antibiotic prophylaxis and cefotaxime vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infections in burned people (sepsis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Non‐absorbable antibiotic prophylaxis vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Infections in burned people (bacteraemia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Non‐absorbable antibiotic prophylaxis and cefotaxime vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infections in burned people (pneumonia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Non‐absorbable antibiotic prophylaxis vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Non‐absorbable antibiotic prophylaxis and cefotaxime vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infections in burned people (urinary tract infection) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Non‐absorbable antibiotic prophylaxis and cefotaxime vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Non‐absorbable antibiotic prophylaxis vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Antibiotic resistance (MRSA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Non‐absorbable antibiotic prophylaxis and cefotaxime vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Non‐absorbable antibiotic prophylaxis vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.23, 20.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Non‐absorbable antibiotic prophylaxis and cefotaxime vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.13, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Length of hospital stay (LOS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Non‐absorbable antibiotic prophylaxis vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [3.28, 10.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Non‐absorbable antibiotic prophylaxis and cefotaxime vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐15.82, 12.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008738-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Local antibiotic prophylaxis (airway)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Infections in burned people (sepsis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Antibiotic prophylaxis vs control/placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Local antibiotic prophylaxis (airway)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008738-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Antibiotic prophylaxis vs control/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Burn wound infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.51, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Topical antibiotic prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.47, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.07, 6.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Systemic antibiotic prophylaxis (perioperative)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.03, 7.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.43, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infections in burned people (sepsis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.54, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Topical antibiotic prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.58 [0.44, 130.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.12, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.49, 9.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Local antibiotic prophylaxis (airway)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.67, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Infections in burned people (bacteraemia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.67, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Topical antibiotic prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.08, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 73.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Systemic antibiotic prophylaxis (perioperative)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.31, 5.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.67, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infections in burned people (pneumonia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.17, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Topical antibiotic prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infections in burned people (urinary tract infection) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.18, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.18, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Infection‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.05, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [1.22, 7.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Systemic antibiotic prophylaxis (perioperative)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 15.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.64 [1.34, 9.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Antibiotic resistance (MRSA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.12, 3.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Topical antibiotic prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.11, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.21, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.39, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.17, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Systemic antibiotic prophylaxis (perioperative)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.42, 6.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.11, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Local antibiotic prophylaxis (airway)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.39, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Length of hospital stay (LOS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐1.27, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Topical antibiotic prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.67 [‐9.46, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Systemic antibiotic prophylaxis (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐1.47, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Systemic antibiotic prophylaxis (perioperative)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐2.64, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Non‐absorbable antibiotic prophylaxis (selective decontamination of the digestive tract) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.43 [2.84, 10.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Antibiotic prophylaxis vs control/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008738.pub2/references#CD008738-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008738.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008738-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008738-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008738-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD008738-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008738-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD008738-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008738-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008738\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008738\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008738\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008738\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008738\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008738.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008738.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008738.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008738.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008738.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726877256"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008738.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726877260"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008738.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9e5e2d00f480',t:'MTc0MDcyNjg3Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 